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Human cardiac troponin I (cTnI) in serum is a well-known clinical biomarker 
for cardiac tissue damage and is used for diagnosing myocardial infarction. 
Unfortunately, commercial cTnI immunoassays from different manufacturers can 
produce significantly different measurement results for the same sample. In order to 
improve the comparability of these measurements, clinical cTnI immunoassays need 
to be standardized. Ultimately, the goal of this work was to develop an isotope 
dilution-liquid chromatography-mass spectrometry (ID-LC-MS/MS) reference 
measurement procedure that could be used to assign concentration values to cTnI 
reference materials. However, given that most serum protein biomarkers are low 
abundant, enrichment was mandatory to successfully quantify cTnI at clinically 
significant concentrations (≈ 1-10 ng/mL). As such, the specific aim of this work was 
to develop enrichment techniques and an ID-LC-MS/MS method to quantify cTnI in 
patient serum samples.  
In order to achieved the required LC-MS/MS sensitivity, novel enrichment 
strategies were investigated to selectively isolate cTnI from serum and plasma. Silica 
  
coated magnetic nanoparticles were synthesized and conjugated with antibodies to act 
as immunoaffinity carriers. Magnetic nanoparticles were selected due to their variable 
surface modifications, high binding capacity, and the fact that they can be easily 
isolated using a magnet. After optimizing the enrichment and digestion procedures, 
isotopically labeled cTnI proteins were used as an internal standard for ID-LC-
MS/MS analysis of cTnI to compensate for variations in the sample preparation. 
Finally, the developed LC-MS/MS-based assay was applied to measure cTnI 
concentrations in patient plasma samples. Effective enrichment methods proved to be 
crucial for achieving quantification of cTnI by ID-LC-MS/MS. To this end, a 
complementary ID-LC-MS/MS method was also developed to evaluate different 
antibody immobilization strategies and magnetic particle types as part of the method 
optimization. Overall, this work demonstrates significant improvements in magnetic 
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Chapter 1: Introduction to the development of enrichment and 
measurement techniques for low abundant protein 
biomarkers 
This chapter has been reproduced in part with permission from: Schneck, N. A., 
Lowenthal, M., Phinney, K. & Lee, S. B. Current trends in magnetic particle 
enrichment for mass spectrometry-based analysis of cardiovascular protein 
biomarkers. Nanomedicine 10, 433-446, doi:10.2217/nnm.14.188 (2015). 
There are an estimated 1.5 million cases of myocardial infarction, commonly 
known as a heart attack, that need medical evaluation every year in the United States 
alone.1 The term myocardial infarction is used within the clinical setting when there is 
evidence of cardiac muscle (myocardial) cell death caused by prolonged ischemia.2,3 
Myocardial infarction is commonly diagnosed by detecting specific protein 
biomarkers, such as the cardiac troponins, that are released into the bloodstream as a 
result of cardiac cell death or damage. One subunit of the cardiac troponin complex, 
cardiac troponin I (cTnI), is a protein that normally functions within myocardial cells 
and is known to be elevated in blood following myocardial injury.4 Due to its high 
myocardial tissue specificity, cTnI is an important biomarker for the diagnosis of 
myocardial infarction. Measurement of cTnI in human plasma or serum by 
immunoassays (e.g. enzyme-linked immunosorbent assay, ELISA) is already a useful 
clinical tool for detecting heart damage; however, cTnI immunoassays need to be 
harmonized and/or standardized, as well as improved with respect to the specificity 
and accuracy of the analytical measurements. Measurement discrepancies between 
different commercial cTnI assays have been previously demonstrated in a number of 





While immunoassays have shown great utility in clinical medicine 
laboratories, there has been interest in implementing liquid chromatography (LC) 
coupled with mass spectrometry (MS, LC-MS, LC-MS/MS)-based detection methods 
to complement immunoassay results. LC-MS/MS assays are attractive due to their 
ability to directly measure the clinical biomarker with improved specificity. However, 
the inherently lower sensitivity of LC-MS/MS techniques relative to immunoassays is 
insufficient for low abundant protein biomarker quantification. As a result, 
enrichment strategies are needed to measure low clinical concentrations of cTnI 
released into the bloodstream after myocardial injury. One common approach towards 
enriching these low abundant biomarkers is through the use of magnetic particle-
based immunoaffinity enrichment approaches. The advantages of magnetic 
nanoparticle-based enrichment make it an ideal method to lower limits of detection of 
current LC-MS/MS instruments for analysis of cTnI. This thesis focuses on 
investigating magnetic-based separation techniques to enrich cTnI for LC-MS/MS 
analysis. With myocardial infarction as a leading cause of death in the developed 
world1, our broad goal is to help improve current clinical cTnI biomarker 
measurements for better patient management and clinical decision-making. 
1.1. Protein biomarkers of myocardial infarction 
Cardiac biomarkers play an essential role in the diagnosis, clinical decision-
making and management of patients with myocardial injury.1,8,9 Since the 1970s, 
proteins such as myoglobin, creatine kinase, and the MB isoenzyme of creatine kinase 
(CK-MB) were utilized clinically as cardiac markers for detecting myocardial cell 




heart.1,10 In the 1990s, cTnI received international endorsement as the preferred 
biomarker for myocardial infarction due to its high specificity for the heart, and has 
become a critical component in the diagnosis of myocardial infarction.10,11 
1.1.1. Cardiac troponin  
Troponin I is a component of the three-subunit troponin complex (sometimes 
designated individually as TnI, TnT and TnC) and plays a key role in the regulation 
of skeletal and cardiac muscle contraction. The troponin complex is located on the 
thin filament of the muscle cell along with other structural proteins like tropomyosin 
and actin.1,12,13 Each troponin subunit has skeletal and cardiac isoforms expressed in 
muscle tissue cells.1,14 Troponin T and troponin I have skeletal and cardiac isoforms 
that differ in amino acid sequence, which allows antibodies to differentiate between 
the different isoforms.10 Additionally, the cardiac-specific troponin I (referred earlier 
as cTnI) isoform, with a molecular mass of 24 kda, differs from its skeletal muscle 
form by an additional 31 amino acid fragment at the N-terminus, and the cardiac 
troponin T (cTnT) isoform differs from its skeletal isoforms by 6-11 amino acid 
residues.15 Conversely, the skeletal and cardiac isoforms of troponin C have the same 
amino acid sequence.10 Therefore, troponin C is not cardiac-specific and is not used 
as a biomarker for myocardial infarction. Because cTnT and cTnI are expressed 
exclusively in heart tissue, these proteins have been the preferred biomarkers for 
diagnosing myocardial infarction.1,10 However, while both proteins have been used as 
diagnostics markers, cTnI is the gold standard among clinicians because cTnT is 
thought to be transiently expressed in some forms of diseased skeletal muscle tissue, 




After myocardial cell damage, the troponin complex is gradually released into 
the bloodstream and degrades into the troponin I-troponin C binary complex and free 
troponin T, as shown in Figure 1.1.5,19-22 In addition, a small amount of soluble 
unbound troponin I and troponin T exists in the cytoplasm and is rapidly released 
after myocardial damage.5,15,23 It is thought that the binary troponin I-troponin C 
complex is the predominant form in circulation.21  
Once in the bloodstream, the various troponin forms undergo substantial 
modifications. The cTnI complex is susceptible to proteolysis, oxidation, reduction 
and phosphorylation.6,24 The N- and C-terminal regions of cTnI are also known to 
undergo proteolytic degradation. However, the central region of cTnI, located 
between residues 30 and 110, has a higher resistance to proteolysis and is very stable. 
The central region of cTnI is thought to be protected from proteolytic degradation 
because this region contains the inhibitory peptide that tightly interacts with cardiac 
Figure 1.1 Schematic representation of cardiac troponins released from a myocardial cell 




troponin C (cTnC).24 Due to this reason, most immunological techniques target the 
central region of cTnI.7,25 
The measurement of cTnI in blood is particularly efficient for late diagnosis of 
myocardial infarction.10 Elevated levels of cTnI can be found in the bloodstream for 
up to seven days after myocardial infarction.10 cTnI levels usually peak around 0.001 
to 100 ng/mL depending on the severity of the myocardial infarction, with highest 
concentrations being observed 18-24 hours after the onset of the infarction.15,26 Since 
the concentration of cTnI is still relatively low even at peak hours, highly sensitive 
detection methods are needed for clinical measurement.23,26 
1.1.2. ELISA as the diagnostic tool for cardiac troponin I (cTnI) 
Even though cardiac troponin was discovered in the 1970’s, the first cTnI 
immunoassay was not described until the late 1980’s by Cummins et al.18,27 
Immunoassays have been heavily relied on for protein quantification within the 
clinical laboratories primarily because of their high sensitivity, high throughput and 
low per-sample cost.28 Two-site “sandwich” immunoassays, (e.g., ELISAs) are 
commonly used to measure protein biomarkers for diagnostic purposes. ELISAs 
entail the use of a capture antibody to bind to the protein of interest and a secondary, 
fluorescently-labeled antibody that is used to detect and measure the amount of 
protein bound to the capture antibody.5 Currently, there is a wide variety of capture 
antibodies specific to several different regions, referred to as epitopes, of the cTnI 
molecule.7,29 The protein concentration can be determined from a calibration curve, 





The first commercialized cTnI assay was introduced in 1996 using the Stratus 
I analyzer (Dade Behring).27 Since then, the cTnI immunoassays have improved 
considerably regarding assay sensitivity and precision. Current generations of 
commercially available assays can reliably measure cTnI at the lower end of the 
reference range (~ 1-10 pg/mL) while meeting precision guidelines (< 10 % 
variation).27,30,31   
 Currently, there are more than 20 immunometric cTnI commercial assays on 
the market and most of these assays are constructed very differently, leading to 
performance variations.7 Commercial cTnI assays vary from each other by the types 
of antibodies used, specificity to different epitopes of the complexed, free and 
modified cTnI, calibrators used, and detection techniques (spectrophotometric, 
fluorescent, chemiluminescent or electrochemical).7,18 As a consequence, cTnI 
measurements from different assays on identical samples can vary 10 to 100-
fold.7,32,33 These assays also suffer from various non-specific interferences such as the 
possibility of anti-cTnI autoantibodies, heterophilic antibodies, anticoagulants and 
other endogenous proteins that may be present in plasma or serum.7,18 These non-
specific interferences can lead to false positives and false negatives.18 Circulating 
autoantibodies in patient samples have been known to confound immunoassays and 
give false-negative results.34-37 For example, anti-cTnI antibodies used for 
commercial assays typically target the stable mid-fragment region (amino acid 
residues 30-110) of cTnI; although, autoantibodies have been observed to block 
capture antibodies from binding to amino acid residues 41-91.35,36 With so many 




For instance, discrepancies between cTnI results obtained using different assays can 
cause problems when a clinician is comparing test results from different laboratories, 
or when laboratories attempt to change assay platforms.26,33   
1.1.3. The need for standardization of cTnI assays 
Standardization of cTnI measurement is needed to achieve comparable results 
between assays and to define common decision limits for cTnI biomarker 
interpretation. Standardization of quantitative measurements in laboratory medicine 
often involves the application of a reference measurement system.7,38,39 The critical 
components of the system include the use of primary and secondary reference 
materials and a higher-ordered reference measurement procedure, as shown in Figure 
1.2.40 The primary reference measurement procedure, which is calibrated using the 
primary buffered-based material, is used to assign a certified value to the secondary 
matrix-based reference material.6,7,38,41-43 Manufacturers can use their own testing 
procedures with the certified (secondary) matrix-matched material to assign values to 
commercial calibrators.7,38 Furthermore, the clinical laboratories can use the validated 
Figure 1.2 Suggested reference measurement system for 




calibrators with their routine procedures to measure cTnI values in patient serum 
samples, which would be traceable to the same reference procedure and materials.7 
The establishment of a reference measurement system for cTnI would ensure 
calibration traceability of cTnI measurements and sample comparability.42  
However, neither a primary reference measurement procedure nor a secondary 
serum-based certified reference material for cTnI has been developed. The cTnI 
Standardization Committee of the American Association for Clinical Chemistry 
collaborated with the National Institute of Standards and Technology (NIST) to 
develop a primary standard reference material (SRM) 2921, consisting of the ternary 
complex of cardiac troponin (cTnC-cTnI-cTnT) extracted and purified from human 
heart tissue under non-denaturing conditions.7,33,41,44 The certified concentration of 
cTnI in SRM 2921 was determined by reverse phase LC and amino acid analysis.33 
An attempt to use SRM 2921 as a common calibrator in commercial assays was tested 
to determine if only a primary reference material was sufficient enough to improve 
harmonization, but the material demonstrated commutability in only 50 % of 
commercial cTnI assays.7,41,45,46 SRM 2921 was made in an attempt to mimic cTnI 
found in patient serum samples; however, a buffered solution of the cardiac troponin 
complex purified from human heart tissue proved to be very different from cardiac 
troponin found in serum.46 Removing the matrix background when purifying cardiac 
troponin for SRM 2921 was also determined to cause structural changes to cTnI, 
which potentially affected immunological behavior and further raised commutability 
issues.6,26 Consequently, a complete reference measurement system, including a 




samples, was needed to calibrate commercial assays.38 In order to certify cTnI values 
in the secondary reference materials, a well-characterized and defined reference 
measurement procedure would be needed.  
An immunochemical procedure using monoclonal antibodies was developed 
as a candidate to support higher metrological order measurements for cTnI.40,42 This 
ELISA-based method displayed suitable linearity, good sensitivity and appeared to 
show no bias when tested on samples with heterogeneous cTnI forms.42 However, an 
ELISA-based procedure was thought to be too dependent on the assay platform 
because it uses an indirect measurement approach.38 ELISA assays coupled with 
fluorescence-based detection measure indirect, nonspecific signals and cannot 
discriminate interferences or protein variants from the target protein.9 Alternatively, a 
non-immunochemical technique, such as targeted LC-MS/MS, can directly measure 
cTnI based on molecular mass and fragmentation patterns with a higher level of 
structural specificity.  
1.2. Targeted mass spectrometry (LC-MS/MS) 
The establishment of reference measurement methods for clinical protein 
biomarkers is usually performed by targeted LC-MS/MS and isotope dilution (ID) 
approaches. There are a variety of LC-MS/MS platforms, but for targeted protein 
quantification the most common is a LC coupled with triple quadrupole MS using the 
multiple reaction monitoring (MRM) technique.47 LC-MS/MS analysis is based on 
protein/peptide mass-to-charge (m/z) ratios and fragment ions, which enable 
unambiguous identification.48 Almost all LC-MRM-MS/MS-based protein 




amendable for the mass spectrometer, which is typically referred to as the bottom-up 
approach. In bottom-up analysis, proteins are digested (e.g. with trypsin) into 
peptides. The resulting peptide mixture can be fractionated using LC and ionized out 
of solution by electrospray ionization for MS detection.49,50 All LC-MS/MS-based 
experiments discussed in this dissertation will involve sample preparation for bottom-
up analysis. 
MRM is a powerful method that exploits the unique capabilities of the triple 
quadrupole MS instrument and provides superior sensitivity and specificity compared 
to other MS platforms. In the MRM method, a particular ion of the targeted 
(precursor) peptide is selected in the first quadrupole and fragmented by collision 
induced dissociation (CID) in the second quadrupole to yield one or several specific 
peptide fragment (product) ions, which are then filtered and measured in the third 
quadrupole.51,52 Several such precursor-product ion pairs, termed MRM transitions, 
can be sequentially and repeatedly monitored during the chromatographic elution of 
the peptide, yielding chromatographic peaks for each transition. Therefore, concurrent 
quantitation can be achieved by integrating the peak intensities of the fragment ions 
for each of the targeted peptides.51 Figure 1.3 demonstrates the detection of a 
representative cTnI peptide using a LC-MS/MS (triple quadrupole) instrument in 
MRM mode. During MRM analysis, the MS focuses exclusively on the targeted 
precursor-product ion pairs and filters outs any co-eluting background ions.53,54 
Therefore, the two levels of mass selection enables high selectivity, and the targeted 
MRM mode translates into higher sensitivity compared to other MS platforms.53 The 




instrument with MRM technology makes it capable of detecting low abundant protein 
extracts from complex mixtures.43,53,54  
 The LC-MS/MS detection of a targeted peptide using MRM scanning relies 
on the correct m/z and peptide sequence.47,51 Peptides are selected to act as 
surrogates/signatures for the protein of interest, which is usually based on information 
obtained from previous LC-MS/MS experiments, scientific literature, and predictive 
software tools.51 Accordingly, section 1.2.1 will briefly introduce the use of another 
LC-MS/MS instrument, a high-resolution hybrid ion-trap-Orbitrap MS/MS, to 
identify amino acid sequences of proteins. In addition, a software program, Skyline55, 
that uses algorithms to generate MRM data for MRM assay development will also be 
introduced.  
1.2.1. Protein and peptide identification by LC-MS/MS and 
bioinformatics tools 
For MRM analysis, unique peptides from the protein of interest must first be 
chosen to act as surrogate peptides for quantification. “Trapping” MS/MS 
instruments, such as the hybrid ion-trap-Orbitrap MS/MS56 are commonly used in a 
Figure 1.3 Overview of targeted LC-MS/MS analysis using MRM. A tryptic peptide (TLLLQIAK) 
uniquely representing cTnI is selected in the first quadrupole (Q1), fragmented in the collision cell 
(Q2), and the fragment (product) ions (LLQIAK and LQIAK) from the third quadrupole (Q3) are 
selected for detection. Precursor-product transition ions can be monitored over time for peptide 




non-targeted approach to identify the best “proteotypic” peptide targets for 
subsequent MRM analysis.57-59 In a typical experimental workflow, a protein sample 
is digested with a proteolytic enzyme (e.g. trypsin) and analyzed by the linear ion 
trap-Orbitrap MS/MS using data dependent analysis. Unlike MRM analysis, data-
dependent methods involve analyzing all of the peptide ions introduced into the LC-
MS/MS at a given time and then selecting the most abundant peptide (precursor) ions 
for fragmentation via CID.60 The resulting fragment (product) ions are then detected 
in an MS/MS spectrum containing m/z values of the fragment ions generated from the 
CID of an isolated peptide ion.57,60,61 Over the entire course of the LC-MS/MS 
analysis, a large dataset of MS/MS spectra can be acquired to identify the protein 
components in a sample.49 Data interpretation by de novo approaches is technically 
challenging and tedious work. Software for interpreting mass spectra (e.g. Sequest62) 
can be used to search each MS/MS spectrum against a protein sequence database to 
identify the amino acid sequences of the peptides found in the sample. The analysis 
software first identifies the individual peptide from a MS/MS spectra and then a set of 
peptide sequences can be used to infer which proteins may be present in the 
sample.60,61,63 Identifying representative peptides and fragmentation patterns for the 
targeted protein can be used to derive MRM transitions based on the precursor and 
product ions. 
Another way to select peptides representative of a protein of interest and 
corresponding MRM transitions is to use predictive tools, such as Skyline.55 Skyline, 
which is a freely available program, predicts MRM transitions based on theoretical 




of the protein sequence, the program automatically generates a list of proteolytic 
peptides (based on an enzyme chosen) and lists the predicted MRM transitions for 
each peptide.55,64,65 
In this dissertation, both computational and experimental workflows were 
used to select tryptic peptides and corresponding transitions for MRM analysis. When 
selecting optimal surrogate peptides to represent the targeted protein, some criteria 
should be considered. For instance, a selected tryptic peptide should be specific to the 
corresponding protein, contain no post-translational modifications, and have good 
LC-MS/MS signal response.47,51 In addition, peptides should have an average length 
of ~10 amino acids. Longer peptides may possess unfavorable LC properties and be 
difficult to synthesize, whereas very short peptides have limited fragmentation ions 
and are often not unique enough for a single protein within a complex mixture.66 
Multiple representative peptides per protein (2-4 peptides with multiple transitions 
per each peptide) are needed for confident MRM analysis to infer the presence of the 
protein and determine protein abundance.51,53,67 Figure 1.4 depicts an overview of 









1.3. Isotope dilution for LC-MS/MS-based quantification 
 LC-MS/MS-based assays (using MRM) in combination with stable-isotope 
labeled internal standards have been extensively used for protein biomarker 
quantification and standardization purposes.69 Specifically, ID-LC-MS/MS is a 
quantitative technique used in reference measurement procedures for many clinically 
relevant proteins.70 Measurements based on ID-LC-MS/MS are more accurate and 
precise because the method requires the use of an isotopically labeled internal 
standard analogous to the target protein/peptide to account for biases associated with 
sample processing and instrument variability.9,70  
Figure 1.4 Overview of designing a LC-MRM-MS/MS experiment using cTnI as a model protein of 
interest. Protein sequence, peptide masses and fragmentation patterns can be determined using 
literature, predictive tools, or data from previous experiments. Crystal structure of cardiac troponin 




The most commonly used ID-based approach relies on spiking the sample 
with isotopically labeled reference peptides at known concentrations and comparing 
signal intensities of native and reference peptides in order to quantify the 
corresponding targeted endogenous protein.47,51 The reference peptides are typically 
synthesized with an incorporated stable isotope label of 13C and/or 15N on one or 
more selected amino acids in the peptide sequence. They have the same 
physiochemical properties as the targeted endogenous peptide, including the 
chromatographic co-elution, ionization efficiency, and fragmentation patterns.47,67 
Unlike immunoanalyzer systems, LC-MS/MS can unambiguously distinguish the 
(light) native peptide from the (heavy) isotopically labeled reference peptide because 
of the defined mass difference. The quantification of the endogenous protein is based 
on the peak area or intensity ratio of the native peptide to the labeled reference 
peptide.47 However, synthetic reference peptides cannot be used to account for biases 
in protein digestion. Accuracy of this approach can be negatively affected if the target 
protein undergoes an incomplete digestion or is partially lost during sample 
preparation.51,71  
To further improve the accuracy of protein quantification, a full-length isotope 
labeled protein, analogous to the target protein, can be spiked into the samples at the 
beginning of the analytical workflow to act as an internal standard. As shown in 
Figure 1.5, the isotopically labeled protein allows for all sample preparation steps to  
be accounted for and decreases any technical variability.53 This approach assumes 
that the native and standard proteins have the same extent of post-translational 




Unfortunately for many clinically relevant proteins, synthesizing an isotopically 
labeled standard protein that has the same post-translational modifications and 
protein-protein interactions as the target protein is quite challenging.70  
 Although ID-LC-MS/MS is the preferred approach to use for a reference 
measurement procedure, current LC-MS/MS-based assays lack the measurement 
sensitivity needed to directly detect low abundant cTnI in human sera/plasma.38 
Therefore, an enrichment step prior to LC-MS/MS analysis is needed to reduce the 
complexity, dynamic range and intrinsic interferences found in biological samples. 
1.4. Limitations for LC-MS/MS detection of cTnI in serum 
 The human plasma proteome is complex and many factors are responsible for 
the difficulty in detecting low abundant proteins in clinical samples by LC-MS/MS. 
One major hurdle is the vast number of proteins and protein modifications that exist 
Figure 1.5 Basic workflow of ID-LC-MS/MS using a full length isotopically labeled protein. The 
recombinant full-length protein containing stable-isotope labels can be spiked in as internal standards. 





in blood.49 Another impediment to LC-MS/MS detection is the wide dynamic range 
of protein concentrations in blood. Protein concentrations in biological samples span 
greater than 10 orders of magnitude, ranging from mg/mL to pg/mL levels whereas 
current LC-MS/MS (triple quadrupole) only span 4-5 orders of magnitude.4,9 At the 
high abundance end, serum albumin (normal concentration 35-50 mg/mL) and 
immunoglobulins account for nearly 55 % and 17 %, respectively, of the blood 
plasma proteome by mass.4,73 Furthermore, 99 % of the total human plasma proteome 
is dominated by the 22 most abundant proteins including albumin and 
immunoglobulins. The remaining 1 % consists of low abundant proteins, such as 
tissue leakage proteins (e.g. the cardiac troponins) or other modified and degraded 
products.4,9,49,72,74 The high abundant proteins can dominate LC-MS/MS detection  
and may suppress or even prevent the detection of proteins at lower concentration 
levels.74  
1.5. Affinity purification strategies 
Currently, LC-MS/MS (triple quadrupole) can detect proteins down to the 0.1-
1 µg/mL range.28,75 However, most clinically relevant biomarkers are present in the 
mid pg/mL to low ng/mL range in serum or plasma and are below the lower limits of 
detection.52 Although LC-MS/MS technology continues to improve, front-end sample 
processing strategies are needed to enhance the overall sensitivity of LC-MS/MS-
based assays and enable the detection of low abundant proteins. Different sample 




1.5.1. Immunodepletion enrichment strategy 
Given the extremely wide dynamic range of protein concentrations in 
biological samples, immunoaffinity depletion of the top high abundant proteins (e.g. 
serum albumin and immunoglobulins) has become a popular strategy to decrease 
sample complexity.76  Columns or cartridges containing immobilized antibodies are 
used to remove up to 58 high abundant proteins from plasma.77,78 By removing 90-  
95 % of the total protein mass, low abundant proteins are enriched.76  For instance, 
combining immunodepletion along with strong cation exchange chromatography has 
been used to reduce the complexity of plasma samples prior to LC-MS/MS detection 
and has successfully lowered limits of quantification to the ng/mL range to measure 
clinically relevant biomarkers including some cardiovascular-related proteins.9,69,79-81  
While immunodepletion columns can deplete the most abundant interfering 
proteins efficiently, there are some caveats that must be considered. Proteins of 
interest can unintentionally bind to either the immunodepletion devices or to the 
depleted proteins (e.g. albumin or other abundant proteins) and negatively impact 
protein enrichment.69,82,83 In fact, cTnI has been shown to interact with abundant 
proteins retained on immunodepletion devices, resulting in low protein recovery.81,84 
The low capacity of most immunodepletion devices is another potential limitation. 
Furthermore, using many antibodies to remove many high abundant proteins 
increases in cost.9,28,69,78,85 A better strategy includes enriching the low abundant 




1.5.2. Immunoaffinity enrichment techniques 
Selective enrichment of target proteins or surrogate peptides by 
immunoaffinity approaches is one of the most effective methods for the sensitive 
detection of low abundant proteins in complex samples. Immunoaffinity purification 
relies on the use of an antibody to capture and recover the analytes (protein or 
peptides) of interest from biological samples.86,87 A major advantage of this technique 
is the highly selective interaction between the antibody and antigen.86 Antibodies 
consist of two identical heavy chains (Fc region) and two identical light chains (Fab 
region) that are linked together by disulfide bonds.  The Fc region is highly conserved 
within each antibody subclass, whereas the Fab region is highly variable between 
different antibodies. This variability in the Fab regions allows the antibodies to bind to 
a wide range of antigens.29 The concept of immunoaffinity-based LC-MS/MS assays 
is similar to that of ELISAs because both rely on the use of antibodies to capture the 
target protein, but the LC-MS/MS acts analogously to the secondary, detection 
antibodies used within ELISAs.76  
The success of immunoaffinity capture depends heavily on which antibodies 
are used in the assay.88 Not all antibodies have the same affinity or specificity for the 
protein/peptide of interest.87 Antibodies can be produced in either monoclonal or 
polyclonal systems.89 Monoclonal antibodies have higher specificity and recognize 
only one epitope on the antigen whereas polyclonal antibodies can detect multiple 
epitopes on the antigen. Due to the higher binding strength, monoclonal antibodies 
typically have higher affinity for their antigen than analogous polyclonal 




interactions, which can result in association equilibrium (Ka) constants usually 
ranging from 105-1012.  Lowenthal et al.90 determined the optimal capture antibody 
for cTnI (SRM 2921) by developing a quantitative LC-MS/MS method to evaluate 
the relative binding affinities of six pre-screened candidate monoclonal anti-cTnI 
antibodies. Clone 19C7 (HyTest, Finland) was selected as the capture antibody for 
future immunoaffinity development work due to its high binding affinity (Ka = 10
7) 
for intact cTnI. As such, this clone was used for protein immunoaffinity enrichment 
in this dissertation. 
1.5.2.1. cTnI protein enrichment 
 Enrichment of cTnI can be performed at either the protein or peptide level. 
Anti-protein monoclonal antibodies, such as clone 19C7, can be used to capture intact 
cTnI in human plasma. Anti-cTnI antibody can be coupled to a solid support (e.g. 
magnetic particles) and incubated within a human plasma sample to capture cTnI. 
The captured proteins can be then released from the antibody and solid support by 
elution (e.g. change in pH) or denaturation (in situ with the magnetic particles during 
trypsin digestion).91 cTnI and any other associated proteins captured in the 
enrichment process can be analyzed by LC-MS/MS.67 Monoclonal antibodies specific 
for human cTnI are readily available by several manufacturers due to the ongoing 
efforts to improve cTnI immunoassays.  
1.5.2.2. cTnI peptide enrichment 
As mentioned earlier, cTnI immunoassays have been confounded by a variety 
of interferences, including antireagent antibodies and endogenous autoantibodies. In 
contrast to the protein-based immunoaffinity strategy, the peptide enrichment-based 




destroyed by the tryptic digestion.28,89 Since protein measurements are usually 
performed at the peptide level, anti-peptide antibodies can be used as an alternative 
enrichment strategy to capture peptides of cTnI for protein quantification.76 In 2004, 
Anderson et al.92 introduced this concept by using immobilized anti-peptide 
polyclonal rabbit antibodies to enrich four blood plasma proteins and their 
corresponding isotope-labeled peptide standards for ID-LC-MS/MS analysis.76 In this 
initial demonstration, human plasma was digested, filtered, desalted and loaded onto a 
nanoliter-sized affinity column immobilized with anti-peptide antibodies. After 
loading/washing, the peptides were eluted and concentrated on a C18-trap column for 
LC-MS/MS analysis.92,93 Anderson et al.92 reported an average 120-fold enrichment 
of the target peptides relative to nontargeted peptides for each protein. This peptide 
enrichment strategy coupled with the ID-LC-MS/MS approach is also known as 
“stable isotope standards (for use with) capture by anti-peptide antibodies” 
(SISCAPA).92,93  
  Typically, polyclonal anti-peptide antibodies are custom produced for peptide 
enrichment instead of using monoclonal anti-peptide antibodies. Monoclonal 
antibody production for several surrogate peptides from the target protein is usually 
too expensive in terms of labor.89 Polyclonal antibodies can be produced against a 
given target by attaching a peptide as a hapten to a carrier protein and injecting the 
conjugate into a laboratory animal (e.g. rabbit).29,89 A carrier protein, such as keyhole 
limpet hemocyanin (KLH), is needed because peptides are generally too small to be 
presented as antigens in mammals, and the carrier protein also serves as an adjuvant 




antibodies can bind with various strengths and to a variety of epitopes on the antigen 
peptide.29 However, some polyclonal antibodies may not have an affinity strong 
enough to enrich its target peptide. Additionally, the antibody production yield may 
be too small for method development and application purposes.89  
1.5.3. Magnetic particle-based separation 
 For the SISCAPA approach, Anderson’s group initially implemented the 
nanoliter-capacity columns immobilized with anti-peptide antibodies to enrich low 
abundant plasma peptides, but later switched to magnetic particles as an alternative 
antibody solid support.92 Anderson et al.94 noted several disadvantages with using 
affinity columns, which included sample-to-sample carry-over after column 
regeneration, concerns with binding kinetics and limited multiplexing for high 
throughput validation studies.9  
Magnetic iron oxide particles coupled with antibodies have been demonstrated 
to effectively isolate and purify low abundant proteins from biological fluids. 
Magnetic particles are particularly effective solid supports for purification procedures 
because of their magnetic properties, high binding surface area-to-volume ratios and 
flexibility to handle large sample volumes.9,95,96 As depicted in Figure 1.6, magnetic 




conjugated with antibodies within the biological sample. During incubation, the 
magnetic particles immobilized with antibodies can selectively capture antigens and 
be isolated from the rest of the sample using a magnetic separator, thereby enriching 
the target antigen for subsequent LC-MS/MS detection.9 The whole separation 
procedure can be performed in the same tube with few handling steps, allowing 
multiple samples to be processed in parallel.  
Magnetic particles can be engineered with small diameters (1 nm -5 µm), 
resulting in high surface area per unit volume. Additionally, the particle surface can 
easily be functionalized to ensure good stability and dispersion in solutions and allow 
for facile antibody immobilization.95 Magnetic particle-based separation techniques 
have many advantages over the standard, non-magnetic separation procedures. The 
most obvious advantage of magnetic particles is their ease of manipulation and ability 
to be magnetized with inexpensive magnets.97 Most magnetic particles behave with 
Figure 1.6 Immunoaffinity with magnetic particles can be performed by targeting protein or peptides 
for enrichment; followed by preparation for LC-MS/MS-based analysis. Workflow A entails capturing 
target proteins from biofluids by using anti-protein antibody. Workflow B entails capturing target 




paramagnetic characteristics and respond to an external magnetic field, but do not 
interact with each other in the absence of an external magnetic field.9,97,98 
Furthermore, magnetic particles enable fast kinetic processes in solution compared 
with bulk solid supports. Magnetic iron oxide particles conjugated with antibodies 
provide a simple, but effective way to enrich antigens from complex serum samples.99  
1.6. Proposed strategies to enrich cTnI for targeted LC-MS/MS 
analysis 
 In this work, an immunoaffinity strategy using magnetic nanoparticles is 
investigated to enrich cTnI from biological samples for LC-MS/MS-based analysis. 
In Chapter 2, we describe the methods used to prepare silica coated magnetic 
nanoparticles. In Chapter 3, we investigate antibody-magnetic particle conjugates for 
protein enrichment and develop a complementary LC-MS/MS-based method to 
evaluate different conjugations and magnetic particle supports. In Chapter 4, a 
protein-based immunoaffinity enrichment strategy combined with an ID-LC-MS/MS 
method is developed to capture and quantify cTnI from patient plasma samples. 
Chapter 5 presents preliminary work involving cTnI enrichment at the peptide level 
and discusses relevant challenges. This dissertation work is a part of a larger effort to 
use LC-MS/MS and magnetic particle-based immunoaffinity techniques to create a 
reference measurement procedure and a serum-based reference material for cTnI with 




Chapter 2: Synthesis of silica coated magnetic nanoparticles 
This chapter has been reproduced in part with permission from: Schneck, N.A.; 
Phinney, K.W.; Lee, SB.; and Lowenthal, M.S. Quantification of antibody coupled to 
magnetic particles by targeted mass spectrometry. Anal. Bioanal. Chem. 
doi:10.1007/s00216-016-9948-3 (2016). 
2.1. Introduction 
The increased use of magnetic-based separations in clinical diagnostics and 
other research applications has led to an array of commercially available and 
synthesized particles with different sizes and functionality types. For instance, 
micron-sized particles (i.e. microbeads) have been extensively used as 
immunomagnetic carriers for capturing protein biomarkers from biological samples 
because commercially available microbeads offer little size variability (< ± 5%) and 
are pre-coupled with surface functionalities for simple antibody immobiliziation.9,99 
However, using magnetic particles smaller than 1 micron (µm) may achieve higher 
capture efficiency, especially for low abundant protein biomarkers, due to their 
relatively higher surface area-to-volume ratio.9,100 Currently, nanoparticles below 200 
nanometer (nm) are commercially available, but are not monodisperse.  
Several chemical methods have now been developed to synthesize magnetic 
iron oxide nanoparticles of various sizes (1 nm- 1 µm) on a small batch scale for a 
wide range of applications. In-solution chemical methods for preparing magnetic 
nanoparticles include co-precipitation, thermal decomposition, and hydrothermal, and 
polyol processes.101,102 The polyol-mediated synthesis is advantageous because this 
approach is capable of producing hydrophilic iron oxide nanoparticles with high 




In the polyol process, iron oxide nanoparticles are synthesized by modified 
reduction reactions between a metal salt (e.g. FeCl3 • 6H2O) and a polyol (e.g. 
ethylene glycol) at refluxing temperatures. In a typical method, FeCl3 • 6H2O is used 
as the iron precursor and ethylene glycol acts as both a polyol and a strong reducing 
agent in the presence of sodium acetate and water.103,105 Sodium acetate plays an 
important role in the formation of spherical particles acting as a hydrolysis agent, an 
alkali and an electrostatic stabilizing agent to prevent particle aggregation.106  
Several groups have studied the formation mechanism of magnetic particles 
using FeCl3 • 6H2O as the iron source and ethylene glycol for the polyol 
process.103,107,108 Iron oxide particles are formed by a two-stage nucleation and growth 
process in the polyol method. In the nucleation stage, ethylene glycol reduces a 
portion of Fe3+ ions to a lower valence state (Fe2+) at high temperatures. Meanwhile, 
the hydrolysis of sodium acetate provides an alkaline environment and forces 
hydrolysis of the metal ions to form Fe(OH)3 and Fe(OH)2.
106,107 Subsequently, the 
metal hydrates undergo dehydration (condensation) and transform into Fe3O4 
nanocrystals. Compared to other polyols, ethylene glycol has a lower reductive 
potential, which slows the formation and growth rate of the iron oxide 
nanoparticles.103 During the formation process, the nanocrystals have enough time to 
rotate with neighboring nanocrystals to obtain a stable surface energy.103,106 
Therefore, after nucleation is achieved, the primary magnetite nanocrystals tend to 
aggregate into larger secondary nanoparticles via oriented attachment. In the second 
growth stage, the iron oxide nanoparticle clusters can then grow based on Ostwald 




hydrophilic nanoparticles of different sizes by either changing the polyol, 
concentrations of the starting materials or reflux time.  
Maximum coverage of antibodies is often observed for magnetic particles 
with diameter sizes around 50 nm, which is approximately five times the diameter of 
an antibody.29  The size range of the magnetic particles should also account for the 
binding of immobilized antibody to a medium-sized target, such as cTnI (cTnI: 24 
kDa, cTnI-cTnC binary complex: 42 kDa, ternary complex: 77 kDa). Furthermore, 
the magnetic property of iron oxide nanoparticles is strongly dependent on size.111 
Too small of a particle size may lower or cease magnetic response, making the 
magnetic particle-based capture inefficient.100 Therefore, a compromise between 
particle diameter/surface area and sufficient magnetic properties is necessary to 
achieve nanoparticles with sizes similar to protein molecules (i.e. ≈ 75 nm in 
diameter), as well as, high enough magnetic susceptibility for fast and complete 
separations.112 
In addition to high magnetic properties, magnetic carriers for immunoaffinity 
enrichment must have good biocompatibility and interactive functions at the surface. 
For that reason, the surfaces of the nanoparticles are typically modified with a 
polymer or silica. The nonmagnetic outer shell also helps stabilize colloidal 
dispersion and provides facile attachment of surface functional groups needed for 
different bioconjugation methods.9,99,100,113 A popular approach to coat magnetic 
particles with silica involves the Stöber sol-gel process, which is based on hydrolysis 
and the polycondensation of an alkoxysilane (e.g. tetraethylorthosilicate, TEOS).114-




surfaces, or silanol groups, that can allow for facile functionalization with silane 
coupling agents.115 It has been reported that the efficiency of silane bonding increases 
when the nanoparticles are coated with a layer of silica.117 Silane coupling agents 
with various functional groups can be utilized to immobilize antibody to the magnetic 
nanoparticles for immunoaffinity enrichment.113 Therefore, the final step in the 
synthesis of magnetic nanoparticles will involve a silica coating process. 
 In this chapter, we demonstrate the preparation of silica coated paramagnetic 
iron oxide nanoparticles using a facile and economic synthesis strategy. We focus on 
controlling the size of the magnetic nanoparticles by changing the water 
concentration in the initial reaction conditions. Finally, the nanoparticles are coated 
with a thin silica shell to allow easy surface modification.112 This work resulted in an 
important method for obtaining hydrophilic, biocompatible iron oxide nanoparticles 
for effective magnetic bioseparations.  
2.2. Experimental method 
2.2.1. Preparation of magnetic iron oxide nanoparticles 
In a typical synthesis, iron (III) chloride hexahydrate, FeCl3 • 6H2O (0.25 g, 
0.025 M), sodium acetate (0.44 g, 0.125 M) and water (1.5 g, 2 M) were dissolved in 
40 mL ethylene glycol and refluxed for 7 hrs. The nanoparticles were magnetically 
separated from solution and thoroughly rinsed with water and ethanol. The 
nanoparticles were dried at 100 °C for 2 hours. Overall, 70 milligrams (mg) of 




2.2.2. Silica coating of magnetic iron oxide nanoparticles 
The silica coating procedure was described previously.118 Bare magnetic 
nanoparticles (30 mg) were dispersed in water (30 mL, pH 4) and ultrasonicated for 
10 minutes. The water was decanted and a mixture (60 mL) of 
ethanol/water/ammonium hydroxide (70 % / 17 % / 13 % volume fractions, v/v/v) 
was added to the nanoparticles; followed by the addition of 40 µL of TEOS. The 
magnetic nanoparticles were sonicated in the resultant mixture for 30 minutes, and 
washed with ethanol and water. The silica magnetic nanoparticles were dried and 
stored at 4 °C. 
2.2.3. Characterization of silica coated magnetic nanoparticles 
 The size and morphology of the bare and silica coated magnetic nanoparticles 
were investigated with a field emission gun transmission electron microscope (TEM; 
JEOL JEM 2100F) operated at 200 kV. Before drying, the silica coated magnetic 
nanoparticles were reconstituted in 30 mL water (final concentration: 1 mg/mL) and a 
500 µL aliquot was added to 20 mL water. The solution was ultrasonicated for 10 
minutes. The nanoparticles were then dispersed in 50:50 ethanol/water mixture and a 
drop of sample solution was placed on a formvar/carbon-coated copper TEM grid. 
ImageJ software was used to analyze the size of the nanoparticles.  
2.3. Results and discussion 
2.3.1. Influence of water concentration on nanoparticle size and 
morphology   
Several previous studies have investigated the polyol-mediated mechanism of 




Various factors in the initial reaction conditions are known to influence the size and 
morphology of the particles. For instance, synthesis parameters, such as the 
concentration of reagents and reflux time, affect the size and shape of the particles. 
Furthermore, a higher concentration of sodium acetate and water can decrease the 
particle size.107,108 By increasing the overall hydroxyl concentration, the hydrolysis 
rate of FeCl3 can be accelerated to generate a larger number of smaller particles.
107,110 
Based on those observations, various concentrations of water ranging from 2.0 M to 
3.2 M were added to the polyol medium to investigate the effect of hydrolysis and the 
size of the nanoparticles. While keeping other reaction conditions constant, the size of 
the iron oxide particles significantly decreased as the water concentration increased 
from 2.0 M to 3.2 M, which is shown in Figure 2.1. The sizes of the bare iron oxide 
nanoparticles ranged from 25 nm to 120 nm. However, as seen in Figure 2.1. (c) and 
(d), a higher water concentration resulted in irregular shaped and more aggregated 
nanoparticles, with a wider particle size distribution. The irregular shape and wide 
size distribution may be caused by hydrolysis/condensation occurring too fast for the 
nanocrystals to uniformly orient into the nanoparticle clusters.119 These results 
demonstrate that water can be used as an additive to decrease the size of iron oxide 




2.3.2. Coating magnetic nanoparticles with silica   
 The magnetic nanoparticles were coated with a thin silica layer using a 
previously described protocol.118 Adding a silica layer improves the stability of the 
nanoparticles in solution and provides reactive silanol groups for covalent bonding of 
various functionalization molecules. A very thin silica layer was sought since the 
nonmagnetic silica layer lowers the magnetic property and surface area-to-volume 
ratio of the magnetic nanoparticle. The thickness of the silica shell was controlled by 
changing the concentration ratio of TEOS to magnetic nanoparticles. Sonication was 
used to minimize aggregation between nanoparticles prior to and during the coating 
Figure 2.1 TEM images of the silica coated magnetic 
nanoparticles prepared with the same molar ratios of 
FeCl3: sodium acetate (0.025 M: 0.13 M) and varying 
concentrations of water (a) 1.3 M, (b) 2.0 M, (c) 2.6 M, 




process to avoid trapping multiple nanoparticles in a single silica shell. As the 
concentration ratio of TEOS to iron oxide nanoparticles decreased from 3.8 to 1.2, the 
thickness of the silica shell decreased from ≈ 30 nm to ≈ 5 nm. Figure 2.2 (b)-(d) 
shows the TEM images of magnetic nanoparticles whose surfaces have been coated 
with silica using different ratios of TEOS to a bulk amount of nanoparticles. It was 
Figure 2.2 TEM images of (a) bare nanoparticles and (b)-
(d) nanoparticles whose surfaces have been coated with as 
silica shell of various thicknesses. The thickness of the 
shell was adjusted by changing the concentration of TEOS 




most convenient and reproducible to adjust the shell thickness by changing the ratio 
of TEOS to nanoparticles, but other parameters, such as growth time, could have been 
changed to control the thickness of the silica shell. The nanoparticles coated with a ≈ 
5 nm silica shell, as shown in Figure 2.1. (b), were prepared for future 
immunoaffinity enrichment experiments.  
Overall, the ultimate synthesis method produced silica coated magnetic 
nanoparticles with an average diameter of ≈ 85 ± 10 nm. Figure 2.3 shows the  
histogram of the particle size distribution with the corresponding TEM image. 
Additionally, the nanoparticles were stable and dispersible in aqueous buffered 
solution when rotary mixed and easily manipulated when an external magnet was 
applied. 
2.4. Conclusion 
Magnetic nanoparticles were prepared by a facile, one-pot inexpensive polyol 
process with tunable diameters ranging from 25 nm to 120 nm. The average size of 
the magnetic nanoparticles could be decreased by increasing the concentration of 





water added to the synthesis. The bare magnetic nanoparticles were coated with silica 
to improve the surface reactivity of the nanoparticles for further antibody 
functionalization. The thickness of the silica surface layer was controlled by varying 
the concentration ratio of TEOS to magnetic nanoparticles. Silica coated magnetic 
nanoparticles with an average size of 85 nm exhibited a narrow size distribution, 
paramagnetism and good dispersion in water, which are all important attributes for 




Chapter 3: Quantification of anti-cTnI antibody bound to 
magnetic particles by LC-MS/MS 
This chapter has been reproduced in part with permission from: Schneck, N.A.; 
Phinney, K.W.; Lee, SB.; and Lowenthal, M.S. Quantification of antibody coupled to 
magnetic particles by targeted mass spectrometry. Anal. Bioanal. Chem. 
doi:10.1007/s00216-016-9948-3 (2016). 
3.1. Introduction 
For antibody immobilization, silica coated magnetic nanoparticles need to be 
functionalized with reactive surface groups that can covalently bind to the target 
antibody. The most commonly employed method for surface modification of silica 
coated magnetic nanoparticles is silanization of a functional moiety, which involves 
reacting an organosilane coupling reagent with the silica surface to produce a 
covalent bond.116,117,120-122 Magnetic particles can be modified with a variety of 
surface functionalities (e.g. terminal amine, aldehyde, epoxy groups) using 
organosilane reagents.97,99 For example, an aminosilane, such as 3-
aminopropyltriethoxysilane (APTES), can be coupled to the surface of the 
nanoparticle and the terminal amino group can be further reacted with glutaraldehyde 
to act as a crosslinker. Antibodies can then be immobilized irreversibly onto the 
glutaraldehyde-activated particles via an amide bond between the amino groups of the 
antibody and the aldehyde of the crosslinker.29 Epoxysilane modification of the 
magnetic nanoparticles via glycidyloxypropyltrimethoxysilane (GPTMS) is another 
preferred method to covalently immobilize antibodies in a convenient, one-step 
reaction.122,123 Figure 3.1 shows a schematic of functionalizing amine and epoxy 





The numerous routes to antibody immobilization makes reliable prediction of 
antibody loading capacities difficult. Many factors, such as the physiochemical 
properties of the antibody and magnetic particles, the antibody immobilization 
method and surface functionality of the magnetic particles, can certainly influence the 
performance of the enrichment. Moreover, adequate amounts of antibody conjugated 
to the surface of magnetic particles is a key factor for efficient protein capture. To 
quantitatively control for variabilities in particle type, surface modification and 
Figure 3.1 Schematic depicting the functionalization of silica coated magnetic particles with common 
coupling agents, (a.) APTES or (b.) GPTMS, to covalently attach antibody by either a glutaraldehyde-




antibody immobilization strategy, it is important to develop general analytical 
methods to accurately quantify the amount of bound antibody.  
Protein assays, such as bicinchonic acid assay and UV-visible 
spectrophotometry have been used frequently for quantifying antibody immobilized 
to magnetic particles.124-127 However, these methods require that the magnetic 
particles first be removed from the sample because the magnetic particles and excess 
surface ligands can interfere with the analysis and cause inaccurate readings.124 
Therefore, the amount of immobilized antibody is inferred by measuring the amount 
of unbound antibody in the supernatant washes.124,126 Other semi-quantitative 
approaches include western immunoblotting and polyacrylamide gel electrophoresis, 
which rely on external calibrants for quantification.127 However, incorporating an 
internal standard control is preferred because it can decrease measurement variability 
and improve precision both within and between measurement assays. The ID-LC-
MS/MS methodology utilizing MRM can be employed to quantify specific tryptic 
peptides derived from the protein and is not subject to biases, such as, differences in 
molar absorptivity or protein size. As described in Chapter 1.3, the peptides can be 
quantitated against a spiked internal standard (i.e. synthetic, stable-isotope labeled 
peptides) to determine protein concentrations. A sensitive ID-LC-MS/MS method that 
can accurately measure antibody loading and is less subject to interference can greatly 
improve the evaluation of various antibody-magnetic particle conjugates. 
Here we present the development of a quantitative ID-LC-MS/MS method to 
directly measure the amount of antibody immobilized onto magnetic particles, which 




magnetic nanoparticles, described in Chapter 2, are activated with glutaraldehyde or 
epoxy surface groups to conjugate anti-cTnI antibody. In order to compare antibody 
coupling efficiency, commercial microparticles pre-functionalized with either amine 
or epoxy groups are also used to conjugate anti-cTnI antibody using the same binding 
chemistries. As predicted, the results demonstrate that nanoparticles more efficiently 
bind antibody when compared to microparticles due to the larger surface area per unit 
mass of the nanoparticles. Furthermore, this ID-LC-MS/MS method is applied to 
evaluate the anti-cTnI antibody-magnetic particle coupling process as part of method 
optimization to ultimately improve cTnI enrichment and subsequent LC-MS/MS 
detection. 
3.2. Materials and methods 
3.2.1. Materials 
Monoclonal mouse anti-cTnI antibody 19C7 was purchased from HyTest Ltd. 
(Turko, Finland). The synthetic isotopically labeled peptides, DLPSPIER and 
TDSFSCNVR, were purchased from AnaSpec, Inc. (San Jose, USA). Dynabeads® 
M-270 Amine and Dynabeads® M-270 Epoxy were purchased from Life 
Technologies (New York, USA). The silane reagents, APTES and GPTMS, were 
purchased from Gelest, Inc. (Pennsylvania, USA). Rapigest™ SF was purchased from 
Waters Corporation (Massachusetts, USA) and sequencing grade modified trypsin 
was purchased from Promega Corporation (Wisconsin, USA). High purity LC-MS 
grade water (H2O)/formic acid and acetonitrile (ACN) /formic acid were purchased 
from Honeywell-Burdick and Jackson (Michigan, USA). All other chemicals were 




3.2.2. Conjugation of antibody to various functionalized magnetic 
particles 
3.2.2.1. Surface modification of the silica coated magnetic nanoparticles 
Silica coated magnetic nanoparticles (1 mg) were treated with 10 % APTES in 
ethanol/water (95 % / 5 % v/v) solution and allowed to react for 30 minutes with end-
over-end rotation. The amine functionalized nanoparticles were washed with ethanol 
and water. The same procedure was also carried out using GPTMS to prepare epoxy 
functionalized nanoparticles. Calculations to determine the theoretical maximum 
number of silane groups per bulk amount of particles were performed, which 
corresponded to the number of functional groups available for antibody binding.128 
3.2.2.2. Antibody coupling to the amine-modified magnetic particle 
Amine functionalized nanoparticles and microparticles (1 mg nanoparticles 
and 33 µL of 30 mg/mL Dynabeads M-270 Amine; 2.8 µm bead size) were treated 
with 2 % (v/v) glutaraldehyde in phosphate buffer solution (PBS, pH 7.4). The 
magnetic particles were rotary mixed for 2 hours and washed three times with PBS. 
The particles were redispersed in PBS and anti-cTnI antibody. The magnetic particles 
were gently vortexed and sodium cyanoborohydride (final: 50 mmol/L) was added. 
The magnetic particles were mixed using a rotary mixer for approximately 24 hours. 
After immobilization, the antibody-magnetic particle conjugates were washed several 
times with PBS and once with ammonium bicarbonate to remove any unreacted 
antibodies. 
3.2.2.3. Antibody coupling to epoxy-modified magnetic particles 
Epoxy functionalized nanoparticles and microparticles (1 mg nanoparticles 




sodium phosphate buffer and incubated for 10 minutes with rotary mixing. The 
particles were washed with sodium phosphate buffer and resuspended in the same 
buffer. Anti-cTnI antibody was added, followed by the addition of ammonium sulfate 
(final: 1 mol/L). The reaction mixture was allowed to incubate for 24 hours with 
rotary mixing. After antibody immobilization, the magnetic particles were washed 
several times with PBS and once with ammonium bicarbonate.  
3.2.3. Calibrant preparation 
External calibrant solutions were prepared at two different ranges for the 
nanoparticle sets and microparticle sets, respectively. The magnetic particle sets were 
carried through the identical functionalization procedures to achieve matrix-matched 
calibration solutions, but were reconstituted with anti-cTnI antibody and ammonium 
bicarbonate (total volume 50 µL) prior to digestion. Calibrants were not washed after 
adding antibody to ensure complete recovery. Anti-cTnI antibody (0.2 µg/mL) was 
added at five different levels ranging from 1 µg to 8 µg to the functionalized 
magnetic microparticles (1 mg). Calibration solutions for the functionalized magnetic 
nanoparticle sets were prepared by adding anti-cTnI antibody (2 µg/mL) at five 
different levels ranging from 10 µg to 100 µg.  
3.2.4. Sample processing for ID-LC-MS/MS analysis 
Calibrants and samples were digested with modified porcine trypsin without 
magnetic particle removal. The samples were denatured with 0.1 % Rapigest™ SF in 
50 mmol/L ammonium bicarbonate (100 µL) and boiled for 2 minutes. The antibodies 
were reduced with a final concentration of 5 mmol/L dithiothreitol (DTT) at 60 °C for 




temperature for 45 minutes. Trypsin was added to the samples (1:10 w/w trypsin-to-
protein ratio) and all samples were incubated for 16 hours at 37 °C. The digests were 
acidified with a final concentration of 5 % (v/v) formic acid for 45 minutes at 37 °C 
and centrifuged at 4 °C to remove the Rapigest™ SF and the magnetic particles. The 
digests were dried using a vacuum centrifuge.  
Dried peptides were reconstituted in 20 µL LC/MS grade H2O / 0.1 % (v/v) 
formic acid containing labeled peptides corresponding to the constant region of anti-




15N]R) were prepared at constant concentrations for 
each magnetic particle support (1.9 µg/µL for nanoparticles and 0.14 µg/µL for 
microparticles). An additional 230 µL LC/MS grade H2O / 0.1 % (v/v) formic acid 
was added to the nanoparticle sample set to dilute final protein concentrations 
similarly to the microparticle sample set (0.05 µg/µL to 0.5 µg/µL). 
3.2.5. ID-LC-MS/MS analysis 
After equilibration, 8 µL of sample was injected for each LC-MS/MS run. 
LC-MS/MS analysis (duplicate injections) was performed on an Agilent 1200 LC 
system coupled in-line with an Agilent 6490 triple quadrupole MS. For the peptide 
measurements, LC separation was performed at a flow rate of 200 µL/min on a 
Zorbax (Agilent) SB-C18 reversed-phase analytical column (2.1 mm x 150 mm, 3.5 
µm particles) at 45 °C using an increasing linear gradient of organic/aqueous solvent 
(ACN/H2O containing 0.1 % (v/v) formic acid) starting at 5 % organic up to 70 % 
organic over 20 minutes, followed by a column wash and re-equilibration. The MS 




predicted amino acid sequence and a predictive MRM software tool (Skyline).55 
Potential tryptic peptides and MRM transitions were assembled for MRM screening 
to determine the most intensive fragmentation transitions for the IgG2b isotype. 
Fragmentation transitions were optimized and monitored for each IgG2b peptide. 
Source and fragmentation parameters were kept identical for analogous isotopically 
labeled and unlabeled peptides. Peak areas were integrated using MassHunter 
Qualitative Analysis B.06.00 software. 
3.2.6. LC-MS/MS antibody sequence analysis for peptide selection 
LC-MS/MS sequencing analysis was used to identify the antibody subclass 
(i.e. IgG1, IgG2a, IgG2b) of monoclonal mouse anti-cTnI antibody 19C7. Antibody 
was digested with trypsin, as described in Section 3.2.4, and analyzed using a Thermo 
Dionex UltiMate 3000 LC system coupled to a Thermo Scientific hybrid LTQ linear 
ion trap-Orbitrap Elite MS/MS. The antibody digest (1.5 µg) was loaded onto a 
Zorbax (Agilent) SB-C18 reversed-phase analytical column (2.1 mm x 150 mm, 3.5 
µm particles) via autosampler. Peptide elution was achieved over a 55-minute linear 
gradient of organic/aqueous solvent (ACN/H2O containing 0.1 % (v/v) formic acid) 
increasing from 5 % organic to 50 % organic over 55 mins, followed by a column 
wash and re-equilibration. Column temperature was maintained at 35 °C. MS data 
was collected in the Orbitrap mass analyzer using data dependent mode with one 
cycle of experiments consisting of one full-MS scan (400 m/z to 2,000 m/z, resolution 
= 30,000), followed by MS/MS data collection in the LTQ linear ion trap of the five 
most intense precursor peaks (Resolution = normal) with dynamic exclusion enabled. 




activation Q of 0.250, and activation time of 10 ms. Source conditions were as 
follows: heater temperature = 275 °C, sheath gas flow rate = 30 units, auxiliary gas 
flow rate = 5 units, spray voltage = 3500 V, capillary temperature = 350 °C, and S-
lens RF level = 60 %. 
MS data was interpreted using the Sequest HT algorithm (built into the 
Proteome Discoverer v1.3 software suite). Data was searched for peptides with 
variable modifications including cysteine carboxyamidomethylation (+57.021 Da) 
and methionine oxidation (+15.999 Da) using a mammalian UniProt protein database. 
3.3. Results and discussion 
3.3.1. ID-LC-MS/MS method development 
The approach used for quantifying bound antibody on magnetic particles by 
ID-LC-MS/MS is depicted in Figure 3.2. After antibody immobilization, the 
Figure 3.2 Schematic illustration of the ID-LC-MS/MS-based workflow to directly measure antibody 




antibody-magnetic particle conjugates were thoroughly washed to remove non-
specifically adsorbed antibodies. The immobilized antibodies were digested with 
trypsin (in situ with the magnetic particles), spiked with internal standard, and 
directly analyzed by LC-MS/MS. Matrix-matched external calibrants consisting of 
antibody and internal standard were also prepared appropriately for quantitative 
analysis. ID-LC-MS/MS analysis was achieved through the use of isotopically 
labeled standards for protein quantification. Tryptic peptides from the constant region 
of the anti-cTnI antibody, part of the IgG2b isotype subclass
90, were selected to act as 
the internal standard for quantification. Specific peptides were chosen by analyzing a 
tryptic digest of the antibody using an ion trap MS/MS. Figure 3.3 shows a total ion 
chromatogram of the digested sample, as well as, the extracted ion chromatograms of 
two tryptic antibody peptides and their corresponding MS/MS fragmentation patterns. 
Based off of this MS/MS data, these two tryptic peptides (DLPSPIER and 
TDSFSC[+57]NVR) and corresponding MRM transitions were assembled for initial 
MRM screening using a triple quadrupole MS/MS.55 Initially, potential tryptic 
peptides were selected based on the following criteria: possess uniqueness to the 
constant region of IgG2b isotype, possess high enough MS/MS signal intensity, 
contain 8-10 amino acid residues, and not contain amino acid residues susceptible to 
chemical modification, such as cysteine or methionine residues. However, during 
MRM screening, it was observed that the criteria had to allow tryptic peptides with 
amino acids susceptible to fixed chemical modifications so that more than one peptide 
could be used for antibody quantification. Two heavy isotope labeled synthetic 




standards. TDSFSCNVR contained a cysteine residue that was alkylated with IAM by 
the manufacturer. In the procedure, antibodies were reduced with DTT and alkylated 
with IAM prior to digestion. IAM is a highly efficient alkylating agent that reacts 
with the free sulfhydryl groups of cysteine residues causing a fixed 
carboxyamidomethylation modification on cysteine.129 To ensure complete alkylation 
of the TDSFSCNVR peptide, MRM transitions for both alkylated and non-alkylated 
versions of the peptide were monitored. MRM signals from non-alkylated (unlabeled) 
TDSFSCNVR were negligible in all sample sets (reaching a level of only 0.3 % of the 
maximum peak intensity); therefore, no correction for alkylation efficiency was 
 
Figure 3.3 (a) Total ion chromatogram (TIC) of a tryptic digest of anti-cTnI antibody. Analysis of the 
digest was performed by LC-MS/MS (ion trap) and searched against a mammalian protein database 
using Sequest HT (Proteome Discover). (b) Two tryptic antibody peptides were selected based on 
signal intensity in the extracted ion chromatograms (subset) within the TIC trace. (c) MS/MS spectra 
of DLPSPIER and TDSFSC[+57]NVR (d) Amino acid sequence of the antibody constant region. The 
two target peptides used for antibody quantification are indicated in red font. The sequence was 





applied during data analysis. LC-MS/MS parameters for MRM analysis of the 
antibody peptides (unlabeled and labeled) were optimized and summarized in Table 
3.1. Two suitable transition pairs were chosen for MRM analysis of each peptide. 
3.3.2. Antibody quantitation on magnetic particles 
Antibodies immobilized onto magnetic particles by two different conjugation 
methods were analyzed using ID-LC-MS/MS with MRM detection. Figure 3.4 shows 
a representative MRM trace of the transitions monitored for the targeted peptides and 
corresponding isotopically labeled internal standard peptides. Target peptide peak 
areas were normalized to the peak area of the isotopically labeled peptide. Peak 
detection and integration were determined based on the following criteria: (1) similar 
retention times among the MRM peaks of the unlabeled and labeled peptides and (2) 
similar peak shape and peak intensity ratios among the MRM transitions between the 
unlabeled and labeled peptides. Ratios of the unlabeled and labeled MRM peak areas 
Table 3.1 Optimized fragmentation parameters for MRM analysis of antibody peptides. 
The fragmentor voltage was set at 380 V. Labeled residues (indicated with an asterisk) 
contained 13C and 15N isotopes. The cysteine amino acid (AA) residues in the unlabeled and 
labeled TDSFSCNVR peptides were alkylated by the manufacturer, which increased the 




were determined by integrating extracted ion chromatograms of each transition. As 
shown in Figure 3.5, calibration curves for each magnetic particle support were linear 
over the concentration range 0.05 µg/µL to 0.5 µg/µL with correlation coefficients 
(R2) > 0.97. Antibody concentrations were back-calculated against the linear equation 
and multiplied by the known amount of internal standard spiked into the sample prior 
to LC-MS/MS analysis. Antibody-magnetic particle conjugates were analyzed in 
triplicate to determine the consistency of antibody loading onto the magnetic particles 
via different conjugation techniques. 
Among the four conjugated magnetic particles, the highest concentration of 
immobilized antibody was obtained by activating the nanoparticles with 
glutaraldehyde groups (44 µg/mg ± 1.4 µg/mg), as shown in Figure 3.6. The epoxide 
coupling process of the nanoparticles produced the second highest concentration of 
Figure 3.4 Representative extracted ion chromatogram for quantification of immobilized 
antibody using the glutaraldehyde coupling protocol with amine functionalized magnetic 
nanoparticles. Two transitions for the unlabeled and labeled targeted antibody peptide 
(TDSFSC[+57]NVR and DLPSPIER) were monitored, along with two transitions of the 
unlabeled TDSFSCNVR to monitor alkylation efficiency. Asterisk indicates the 




immobilized antibody (27 µg/mg ± 5.3 µg/mg). The lower amount of antibody bound 
to the epoxy-functionalized nanoparticles may be a result of partial epoxy ring 
opening during the silanization procedure and slower kinetics of the epoxy-amine 
reaction.130  
Overall microparticles produced a lower immobilization amount when used as 
the solid support due to the greater surface area of the nanoparticles. Unlike the 
nanoparticles, the epoxy-modified microparticles (3.3 µg/mg ± 0.49 µg/mg) 
performed slightly better than the amine-modified microparticles activated with 
glutaraldehyde (1.5 µg/mg ± 0.20 µg/mg). It is speculated that this is due to the 
additional conjugation step required to functionalize the amine-modified 
microparticles. According to the vendor’s description of materials, the microparticles 
Figure 3.5 Calibration curves for each magnetic particle support are provided for monitored anti-cTnI 
antibody peptide transitions as a plot of unlabeled : labeled integrated peak area ratios versus unlabeled 
: labeled measured mass ratios. A regression equation of the best-fit line is provided for each plot 
along with a R2 estimate of the correlation for fit to the line. The error bars represent standard deviation 




were coated with a layer of glycidyl ether (epoxy) functional groups. The amine-
microparticles were then activated with amine groups using a short linker. In the case 
of the nanoparticles, silane reagents bearing either amine or epoxy functional groups 
were used to directly functionalize the nanoparticles via a one-step silanization 
reaction. Furthermore, the higher antibody binding per mg of nanoparticles in 
comparison with the microparticles was expected because the surface area/mass of 
nanoparticles was much higher than that of the microparticles.  
Based on the data, the amine modified nanoparticles (85 nm) and 
microparticles (2.8 µm) activated with glutaraldehyde correlated well with the 
calculated surface area-to-mass ratios (≈ 30:1), while the epoxy case did not. 
Additionally, the magnetic nanoparticles had < 10 % size variability, which was a 
slightly larger size variation compared to the commercial microparticles. This could 
Figure 3.6 Bar graph summarizes the amount of immobilized anti-cTnI 
antibody per mg of nanoparticles and microparticles. Quantification 
was based on monitoring two transitions for two antibody peptides. The 
standard deviation error bars represent duplicate injections of all of the 




have compromised the reproducibility of the immobilization process. Antibody-
particle conjugates were prepared in triplicate, but no significant differences were 
observed in bound antibody yields. On the basis of the results obtained, it was evident 
that particle size, composition and functionality effect antibody efficiency on a bulk 
mass scale.  
3.3.3. Optimization of antibody-magnetic particle conjugates 
Given that the highest amount of immobilized antibody was obtained by the 
glutaraldehyde-activated nanoparticles, this antibody-magnetic nanoparticle conjugate 
protocol was chosen for further optimization. As such, a quantitative ID-LC-MS/MS 
assay was developed to determine the amount of antibody required to efficiently 
saturate a given amount of nanoparticles. An increasing amount of anti-cTnI antibody 
(7.5, 18, 37.5, 75, 150, 225, 300, 375 µg) was incubated for 48 hours with a fixed 
amount of magnetic nanoparticles (0.25 mg) in a fixed volume (375 µL). Due to the 
high cost of antibody, the coupling protocol was cut by one fourth for optimization 
studies. The amount of antibody bound to the glutaraldehyde-activated magnetic 
nanoparticles was performed using the described ID-LC-MS/MS method. According 
to Figure 3.7, the amount of immobilized antibody increased up to 18.4 µg/mg ± 
0.931 µg/mg for 0.25 mg nanoparticles using 150 µg of antibody. Therefore, 600 µg 
of antibody per mg of glutaraldehyde-activated magnetic nanoparticles (scaled up by 




3.3.4. Advantages of the developed ID-LC-MS/MS method 
Measuring antibodies immobilized to magnetic particles by ID-LC-MS/MS 
has several advantages in comparison with other semi-quantitative protein assay 
methods. For instance, protein assays with conventional optical detection methods, 
such as UV-visible spectrophotometry, cannot discriminate the antibody from 
interfering compounds that adsorb at the same wavelength. Many protein assays are 
prone to interferences from reagents used during the antibody-magnetic particle 
coupling process.131 Therefore, the choice of protein assay depends on many factors 
including tolerance to interfering compounds and reagent compatibility. In addition, 
most commercial antibodies are not provided with accurate extinction coefficients; 
therefore, antibody concentrations are estimated relative to the antibody standards. 
Figure 3.7 Glutaraldehyde-activated magnetic nanoparticles (0.25 
mg) were incubated with an increasing amount of anti-cTnI antibody. 
Antibody binding capacity was determined using a ID-LC-MRM-
MS/MS method specific for anti-cTnI antibody. The standard 
deviation error bars represent duplicate injections of all of the 




Particularly for the epoxy coupling process, the immobilization supernatant and the 
wash supernatant consisted of different buffers, which would warrant a calibration 
curve series for each buffer using a protein assay. However, the developed method 
described uses LC-MS/MS detection, which can distinguish targeted peptides (both 
unlabeled and isotopically labeled corresponding to the antibody) from other 
components in the sample. The ID-LC-MS/MS methodology does not rely on the use 
of an extinction coefficient for absolute quantification, but instead directly measures 
targeted peptides based on molecular mass and fragmentation patterns. Therefore, this 
newly developed method can be applied as a universal approach to quantify the 
amount of antibody on magnetic particles in one measurement (per sample) that is 
independent of the coupling and washing processes, magnetic particle or antibody 
type. 
Another notable advantage is that this LC-MS/MS method can be utilized to 
measure anti-cTnI antibody peptide concentrations simultaneously with cTnI peptide 
concentrations within the sample, which can help account for variations caused by the 
antibody-magnetic particle conjugates. Reproducibility of the enrichment step is 
highly dependent on the antibody-magnetic particle conjugates. As shown in Figure 
3.8, monitoring anti-cTnI antibody peptides simultaneously with immuno-extracted 
cTnI during LC-MS/MS analysis can help provide quality assurance of the magnetic 
separation-based enrichment process.91 The amount of antibody observed in each 
sample should be consistent for reproducible magnetic-based enrichments. This 
method is sensitive enough to monitor antibody differences found between samples 




conjugates.90,91 Overall, this method can be used to evaluate antibody coupling 
processes with different magnetic particles and also help support enriched cTnI 
quantification by LC-MS/MS analysis, which will be discussed in Chapter 4. 
3.4. Conclusion 
Optimizing experimental design for antibody immobilization to magnetic 
particles is crucial for improving low abundant protein enrichment for subsequent 
LC-MS/MS detection. Here, an ID-LC-MS/MS method was developed to directly 
measure the amount of antibody covalently bound to magnetic particles in order to 
select the most efficient coupling procedure. The practical application of the ID-LC-
MS/MS methodology was demonstrated to evaluate various antibody coupling 
Figure 3.8 Representative total ion chromatograms of five cTnI samples enriched using magnetic 
nanoparticles conjugated with anti-cTnI antibody. MRM transitions for two cTnI peptides and one 
anti-cTnI antibody peptides are monitored. LC-MRM-MS/MS detection can be used to monitor 
antibody differences found between sample replicates, which may affect capture recoveries. A higher 
(relative) concentration of antibody (DLPSPIER) peptide was calculated in Sample 1 compared to the 




processes to magnetic particles of micrometer and nanometer dimensions. Antibody 
conjugation was achieved using glutaraldehyde or epoxy coupling processes with 
either nano- or microparticles. The results indicated that the nanoparticles conjugated 
significantly higher yields of antibody independent of the binding chemistry in 
comparison to the microparticles. The glutaraldehyde coupling process with the 
amine-functionalized silica coated magnetic nanoparticles was chosen for the cTnI 
capture procedure due to the high antibody coupling efficiency.  
The primary advantages of this newly developed method are that (1) it can be 
used to measure bound antibody with various magnetic particle types and 
immobilization strategies, (2) it can be used in conjunction with cTnI LC-MS/MS 
analysis by simultaneously monitoring tryptic peptides from the anti-cTnI antibody to 
ensure batch-to-batch consistency of the magnetic separation, and (3) this method is 
transferrable to any LC-MS/MS-based assay using the same antibody isotype. In 
Chapter 4, this method will be used to monitor quality assurance of the enrichment 
step for cTnI quantification.  The generic nature of this approach also suggests that it 
can be applied to any antibody as long as the subclass of the antibody can be 
determined and peptides from the antibody can be uniquely identified from the tryptic 




Chapter 4: Quantification of cTnI in human plasma by protein 
immunoaffinity capture and LC-MS/MS 
This chapter will be reproduced in part with permission from: Schneck, N.A.; 
Phinney, K.W.; Lee, SB.; and Lowenthal, M.S. “Quantification of cardiac troponin I 
in patient plasma by magnetic particle enrichment and targeted mass spectrometry.” 
In preparation. 
4.1. Introduction 
 cTnI is a well-established diagnostic biomarker for heart muscle damage and 
is routinely analyzed by immunoassays in clinical laboratories to assess patient 
samples. However, the broad-scale use of immunoassays on various technology 
platforms from different vendors has resulted in considerable variability in cTnI 
measurements, which influences the interpretation and comparison of results.33,132 
Therefore, it is critical to develop reference materials and reference measurement 
procedures to improve the accuracy and comparability of cTnI measurement results. 
 In this chapter, the development of a highly selective and sensitive ID-LC-
MS/MS-based candidate reference measurement procedure is described to quantify 
cTnI in clinical samples from myocardial infarction patients. ID-LC-MS/MS has been 
extensively used as a reliable measurement method for standardization efforts. Unlike 
immunoassay detection methods, LC-MS/MS in MRM mode can directly detect 
defined m/z’s of surrogate cTnI peptides, generated by enzymatic digestion, with a 
high level of specificity and sensitivity.94 Additionally, absolute quantification of 
cTnI by ID-LC-MS/MS can be achieved based on the peak area ratios of each 
surrogate peptide to its internal standard analog. An internal standard can account for 




 However, LC-MS/MS analysis of low abundant cTnI levels in patient samples 
is challenging due to the vast number of proteins found in plasma or serum, and the 
wide dynamic range of protein concentrations, which spans more than ten orders of 
magnitude.49 Compared to some high-sensitivity cTnI immunoassays that have 
achieved limits of quantification in the low pg/mL range, current LC-MS/MS 
instruments can only directly detect proteins with concentrations at low µg/mL to the 
high ng/mL levels in complex matrices.28,75,134 To improve signal-to-noise (S/N) ratio, 
a protein immunoaffinity enrichment technique utilizing magnetic separation was 
developed to simultaneously enrich cTnI and reduce sample complexity. By including 
an immunoaffinity enrichment step prior to LC-MS/MS analysis, limits of 
quantification can be lowered to the low ng/mL range or below for reproducible 
measurement of cTnI. 
 Quantification of cTnI can be also improved by performing LC-MS/MS 
analysis in dynamic MRM mode. MRM data is typically collected by sequentially 
cycling through all of the MRM transitions, each with their own dwell time (a 
specified collection time to analyze a specific MRM transition), during the entire LC-
MS/MS run.64 Dynamic or triggered MRM analysis only monitors transitions of a 
specific peptide when eluted off the HPLC column at specific retention time 
windows, which optimizes dwell time and improves data quality.135 Using the 
dynamic MRM approach, cycle and dwell time can be maximized for each peptide at 
its unique retention time.64 Since transitions are only triggered at a known retention 
time corresponding to when they are eluted off the HPLC column, several MRM 




measurement precision of the individual peptides.64,136 Additionally, measurement of 
multiple tryptic peptides with different retention times can be easily achieved using 
dynamic MRM since no change in cycle or dwell times is needed. 
Here, an immunoaffinity-based ID-LC-MS/MS assay was developed to 
measure surrogate tryptic peptides of cTnI in either serum or plasma. Key steps in the 
workflow, such as protein capture, digestion conditions, and LC-MS/MS instrument 
parameters, were optimized to enhance the enrichment of cTnI and subsequently 
improve LC-MS/MS detection. During method development, isotopically labeled 
cTnI peptides acted as the internal standard and were used to perform recovery 
studies. However, in the final workflow an isotopically labeled cTnI protein internal 
standard was used in order to avoid correcting for peptide recovery during cTnI 
quantification. The isotopically labeled cTnI protein internal standard corrected for 
protein losses throughout the enrichment process and compensated for digestion 
variability. Following method optimization, a proof-of-concept analysis was 
performed in which elevated levels of cTnI were quantified in five myocardial 
infarction patient plasma samples. 
4.2. Experimental design 
4.2.1. Materials 
Standard Reference Material (SRM) 2921 – human cardiac troponin complex, 
a primary reference material in a buffered solution – which was extracted from 
human heart, was obtained from NIST. Monoclonal antibody against human cTnI 
(clone 19C7) was purchased from HyTest Ltd. (Turko, Finland). The synthetic, 




were purchased from AnaSpec, Inc. (California, USA). The isotopically labeled cTnI 
protein internal standard was expressed and labeled using cell-free E. coli lysate and 
purified by Promise Advanced Proteomics (Grenoble, France). cTnI-negative 
(undetectable cTnI by ELISA) and cTnI-positive patient plasma (heparinized) 
samples were provided through the Department of Laboratory Medicine at the 
University of Washington in Seattle, USA. All cTnI samples used were de-identified 
from clinical routine testing at the University of Washington and human subjects 
research determination forms can be found in Appendix A. A de-identified donor 
plasma pool with Na+ heparin (anti-coagulant), collected from 50 apparently healthy 
individuals, was also obtained through Golden West Biologicals, Inc. (California, 
USA). Goat serum, collected from a controlled donor herd, was purchased through 
Sigma Aldrich (Missouri, USA). Rapigest™ SF was purchased from Waters 
Corporation (Massachusetts, USA) and trypsin gold, MS grade, was purchased from 
Promega Corporation (Wisconsin, USA). High purity LC-MS grade water 
(H2O)/formic acid and acetonitrile (ACN) /formic acid were purchased from 
Honeywell-Burdick and Jackson (Michigan, USA). Protein LoBind centrifuge tubes 
were purchased from Eppendorf (New York, USA). All other chemicals were 
purchased from Sigma-Aldrich (Missouri, USA). 
4.2.2. Immobilization of anti-cTnI monoclonal antibody onto magnetic 
nanoparticles 
Monoclonal anti-cTnI antibody was immobilized on the magnetic 
nanoparticles using the glutaraldehyde method, as described in Section 3.2.2. After 
conjugation, the supernatant was discarded and the antibody-nanoparticle conjugates 




unreacted aldehyde groups. Next, the antibody-nanoparticle conjugates were 
incubated in PBS containing 0.2 % (w/v) BSA/ 0.05 % (v/v) Tween 20 (1.5 mL) for 
16 hours at room temperature to block any additional unreacted sites and limit non-
specific binding. Finally, the antibody-nanoparticle conjugates were washed three 
times with PBS containing 0.1 % (w/v) BSA/ 0.05 % (v/v) Tween 20 and 
reconstituted in PBS (0.5 mL). The resultant nanoparticle sample contained 2 mg/mL 
nanoparticles and approximately 75 µg of anti-cTnI antibody conjugated to the 
surface of 1 mg nanoparticles. Three batches of antibody-magnetic nanoparticle 
conjugates were prepared simultaneously and combined to form one lot of anti-cTnI 
antibody-nanoparticle conjugates for use in cTnI capture studies. 
4.2.3. Calibrant and sample preparation for recoveries studies 
For recovery studies, human cardiac troponin complex from NIST SRM 2921 
stock was thawed to room temperature and prepared gravimetrically by diluting SRM 
2921 in 0.05 % (w/v) BSA solution in ammonium bicarbonate. For the calibrants, 
anti-cTnI antibody conjugated nanoparticles were placed into centrifuge tubes, and 
the supernatant was removed by magnetic separation. SRM 2921 solution was added 
at discrete amounts (e.g. ≈ 2.5, 6.0, 12, 18, 24, 30, 36 ng) and diluted up to 40 µL 
with 0.05 % BSA in ammonium bicarbonate solution. For only these recovery 
studies, the calibrants did not undergo the enrichment or wash steps to ensure 
complete recovery. 
Samples were prepared by spiking known amounts of SRM 2921 into either 
0.2 % BSA/PBS (0.9 mL), goat serum (0.9 mL) or human donor plasma (0.9 mL). 




samples. To capture cTnI, 30 µL of anti-cTnI antibody-magnetic nanoparticle 
conjugates were added to the samples, and incubated at room temperature with gentle 
rotary mixing. Following incubation, non-specific proteins were removed by washing 
the nanoparticles two times with tris buffer (20 mmol/L tris, 150 mmol/L sodium 
chloride) containing 0.05 % Tween 20 (1.8 mL) and once with ammonium 
bicarbonate (1.8 mL). The samples were resuspended in ammonium bicarbonate (40 
µL) for digestion. 
4.2.4. Calibrant and sample preparation for patient plasma sample 
analysis using an isotopically labeled protein internal standard 
Human cardiac troponin complex from NIST SRM 2921 stock was thawed to 
room temperature. SRM 2921 stocks were prepared gravimetrically by diluting SRM 
2921 in 0.1 % BSA solution in PBS (BSA/PBS). Isotopically labeled cTnI internal 
standard was also prepared in 0.1 % BSA/PBS. Patient plasma samples were thawed 
and equilibrated to room temperature. Patient plasma samples were centrifuged for 10 
minutes at 5000 g to sediment any precipitated material. Matrix-matched calibrants 
were prepared gravimetrically by mixing pooled cTnI-negative patient plasma (0.9 
mL) with a range of concentrations of SRM 2921 and a constant concentration of 
isotopically labeled cTnI internal standard. Calibrants were diluted 2-fold in PBS 
(final volume 1.8 mL). Samples were prepared gravimetrically by mixing cTnI-
positive patient plasma (0.9 mL) with the same constant concentration of isotopically 
labeled cTnI internal standard. Samples were diluted 2-fold with PBS (final volume: 
1.8 mL). cTnI was then enriched from the patient plasma samples and calibrants, as 




4.2.5. Trypsin digestion  
Captured proteins were digested in situ with the antibody conjugated 
nanoparticles. The samples and calibrants were denatured in 0.2 % (v/v) Rapigest™ 
SF surfactant in 50 mmol/L ammonium bicarbonate (40 µL) and boiled for 2 minutes. 
The released proteins were reduced with a final concentration of 10 mmol/L DTT at 
60 °C with shaking for 45 minutes, and alkylated with 10 mmol/L IAM in the dark at 
room temperature for 45 minutes. Trypsin was added to the samples (1:2.5 w/w 
trypsin-to-protein ratio) and all samples were incubated for 16 hours at 37 °C. The 
digests were acidified with a final concentration of 5 % (v/v) formic acid for 45 
minutes at 37 °C and centrifuged at 4 °C to remove the Rapigest™ SF and the 
magnetic particles. The digests were dried using a vacuum centrifuge.  




15N]R) were prepared at constant 
concentrations at about a 1:1 ratio with the midpoint of the calibration curve and used 
as internal standards. Calibrants and samples were reconstituted with the isotopically 
labeled peptide internal standard solution (10 µL) prior to LC-MS/MS analysis. 
For studies utilizing the isotopically labeled protein internal standard, 
calibrants and samples were reconstituted with isotopically labeled 
DLPSPIE[13C5,
15N]R internal standard solution (10 µL). As described in Chapter 3, 
DLPSPIE[13C5,
15N]R was a surrogate peptide for the anti-cTnI antibody and was used 
throughout the experiments to determine the relative amount of antibody in each 




4.2.6. LC-MS/MS analysis 
 LC-MS/MS (ion trap) sequencing analysis was used to determine unique cTnI 
peptides and CID fragmentation patterns. A tryptic digest of SRM 2921 was analyzed 
using a Thermo Dionex UltiMate 3000 LC system coupled to a high resolution 
Thermo Scientific hybrid LTQ linear ion trap-Orbitrap Elite MS/MS with the same 
method and parameters as described in Section 3.2.3.  
 LC-MS/MS (dynamic MRM) analysis was performed on an Agilent 1200 LC 
system coupled in-line with an Agilent 6490 triple quadrupole MS. For peptide 
measurements, 8 µL of sample was injected via autosampler and the LC separation 
was performed at a flow rate of 200 µL/min on a Zorbax (Agilent) SB-C18 reversed-
phase analytical column (2.1 mm x 150 mm, 3.5 µm particles) at 35 °C using an 
increasing linear gradient of organic/aqueous solvent (ACN/H2O containing 0.1 % 
(v/v) formic acid) starting at 5 % organic and increasing up to 70 % (v/v) organic 
over 30 minutes, followed by a column wash and re-equilibration. The MS was 
operated in a positive-ion polarity. The following MS settings were used: fragmentor 
380 V, cell accelerator 4 V, electron multiplier 800 V, capillary voltage 3500 V. 
Dynamic MRM scan type was used with a delta retention time of 1 minute for 
(unlabeled and labeled) NITEIADLTQK, TLLLQIAK, DLPSPIER peptides and a 
delta retention time of 3 minutes for (unlabeled and labeled) AYATEPHAK peptide. 
Collison energies were optimized experimentally for each peptide transition by MRM 
monitoring and noting maximum signal intensity. Two fragmentation transitions were 




and one antibody peptide (DLPSPIER) for both the isotopically labeled and unlabeled 
peptides in the final method.   
Peak areas were integrated using MassHunter Qualitative Analysis B.06.00 
software. The concentration of cTnI was determined by generating calibration curves 
using SRM 2921 as the calibrant and plotting peak area ratios of unlabeled to labeled 
cTnI peptide versus known mass ratios of unlabeled to labeled cTnI peptide. Peptide 
concentrations were interpolated against the linear equation and multiplied by the 
known concentration of internal standard. The average concentration of all peptides 
detected using multiple transitions was used to determine cTnI concentration since 
peptide abundance is used as a surrogate for protein abundance.  
4.3. Results and discussion 
4.3.1. Development of the LC-MS/MS-based assay 
To determine surrogate peptides that could represent cTnI, SRM 2921 – 
human cardiac troponin complex (cTnI, cTnT, cTnC) – was digested and analyzed 
using LC-MS/MS (ion trap). Accordingly, the subsequent MS/MS data was analyzed 
against an in silico protein sequence database using Sequest HT to identify peptide 
sequences. Figure 4.1 shows a total ion chromatogram of the protein digest and an 
extracted ion chromatogram of a surrogate cTnI peptide (TLLLQIAK), along with the 
peptide sequence and its MS/MS fragmentation pattern. A total of 23 peptides were 
identified, which provided a combined sequence coverage of 68 % of cTnI, as 





A targeted LC-MS/MS with MRM analysis, using the triple quadrupole MS, 
was performed on the protein (SRM 2921) digest to screen for the most intense MRM 
signals from a panel of tryptic cTnI peptides. As demonstrated in Figure 4.3, twenty 
transitions corresponding to a total of eight cTnI peptides and two modified cTnI 
peptides were selected for LC-MS/MS evaluation. Of the 10 total peptides, 
CQPLELAGLGFAELQDLCR, NIDALSGM(oxidized)R, and 
ISADAM(oxidized)M(oxidized)QALLGAR peptides were not ambiguously detected 
during MRM screening and not selected to be used in the LC-MS/MS-based assay. 
Figure 4.1 (a) Total ion chromatogram (TIC) of a tryptic digest of human cardiac troponin complex 
from SRM 2921. (b) Representative extracted ion chromatogram of tryptic cTnI peptide, TLLLQIAK. 




TLLLQIAK and NITEIADLTQK peptides were selected to be used for 
quantification of cTnI during method development and optimization. Both peptides 
were unique to cTnI, did not possess known post-translational modifications, and 
were reproducibly detected in samples of trypsin digested SRM 2921. Additionally, 
the peptides and their respective MRM transitions produced the highest S/N ratios, 
which allowed for improved sensitivity of the LC-MS/MS method. The MRM 
transition ions chosen to analyze the cTnI peptides by LC-MS/MS are listed in Table 
4.1. Additionally, DLPSPIER, a peptide from the anti-cTnI antibody, was monitored 
and used as a qualitative control to assess the antibody-magnetic particle enrichment, 
as described in Chapter 3. The sensitivity of the method was further enhanced by 
optimizing instrument parameters, such as collision energies and source parameters.  
Virtually all LC-MS/MS-based quantitation work is performed exclusively at 
the peptide level.137 Since digestion conditions can significantly influence peptide 
formation yields, it was imperative to optimize the trypsin digestion protocol. In order 
to enhance sample recovery by limiting clean-up steps, Rapigest™ SF (surfactant) 
was chosen to act as the denaturant since its degradation products could easily be 
removed by acidification and centrifugation.138 After denaturation, proteins were 
Figure 4.2 Amino acid sequence of human cTnI. Peptides in blue were identified from a 
digest of SRM 2921 (human cardiac troponin complex) during sequence coverage analysis 
by LC-MS/MS (ion trap). Tryptic peptides underlined were selected for subsequent MRM 




reduced with DTT and alkylated with IAM under three different conditions (blue: 10 
mM DTT, 10 mM IAM; red: 5 mM DTT, 15 mM IAM; and green: 0.5 mM DTT, 2 
mM IAM, 1.5 mM DTT); followed by the addition of trypsin at enzyme-to-protein 
ratios of 1:2.5, 1:5, 1:10, 1:20, and 1:50. Promega trypsin gold, MS grade was used to 
avoid increasing chemical background from autolysis of the enzyme.139 As depicted 
in Figure 4.4, digestion conditions were optimal when proteins were reduced with 10 
mM DTT and alkylated with 10 mM IAM. Highest peak area ratios were obtained for 
the NITEIADLTQK and TLLLQIAK peptides using a 1:2.5 trypsin-to-protein ratio. 
Figure 4.3 Extracted ion chromatogram of tryptic cTnI peptides screened for MRM analysis and assay 
development. Two transitions per cTnI peptide were analyzed. The blue highlighted tryptic peptides 
NITEIADLTQK and TLLLQIAK produced the highest signal response in electrospray LC-MS/MS 
(triple quadrupole). These peptides are referred to as “surrogate peptides,” and were used to build a 
MRM-based assay for cTnI. Isotopically labeled versions of these peptides were synthesized to act as 




The digestion parameters were further optimized with antibody-magnetic 
nanoparticle conjugates present in the sample. Captured proteins from the enrichment 
step were released from the magnetic nanoparticles via denaturation to decrease the  
risk of potential protein loss that may occur if an elution step was instead used. 
Eluting the captured proteins prior to digestion would have entailed an additional tube  
transfer and drying step.  After the trypsin digestion, Rapigest™ SF degradation 
products and the magnetic nanoparticles were removed simultaneously by 
centrifugation and magnetic separation. Traditional protein digestion methods for LC-
MS/MS analysis typically use an enzyme-to-protein ratio between 1:10 and 1:100; 
however, excess trypsin was required to produce higher peptide formation yields in 
the presence of the antibody-magnetic nanoparticle conjugates.138  
 
Table 4.1 Optimized MS parameters and two peptides (unlabeled and labeled) with two 
transitions each were selected to represent cTnI and a single peptide (unlabeled and labeled) with 




Following optimization of the protein digestion, the limits of detection and 
quantification of the LC-MS/MS system were determined by digesting SRM 2921 at 
various concentrations with a constant amount of antibody-magnetic nanoparticle 
Figure 4.4 Effect of digestion condition on peptide formation yield. Bar graphs 
represent the peak area ratio of the unlabeled peptide to the spiked-in labeled 
peptide. Reduction and alkylation conditions were varied: 10 mM DTT, 10 mM 
IAM (blue line), 5 mM DTT, 15 mM IAM (red line), and 0.5 mM DTT, 2 mM 
IAM, 1.5 mM DTT (green line). For each of the reduction and alkylation 
conditions, the trypsin-to-protein ratios were varied (1) 1:2.5, (2) 1:5, (3) 1:10, (4) 
1:20, (5) 1:50. Data and error bars represent the mean and standard deviation for 




conjugates. Representative extracted ion chromatograms of digested SRM 2921 
samples with final concentrations of 0.0203 ng/µL and 0.0403 ng/µL are presented in 
Figure 4.5.  
By injecting almost all of the sample (i.e., 8 µL injection volume of 10 µL 
sample volume) into the LC-MS/MS system, the absolute limit of detection was 
calculated to be 163 pg cTnI (S/N ≥ 3 for each MRM transition), and the limit  
of quantification was estimated to be 325 pg cTnI (S/N ≥ 10 for each MRM 
transition). Therefore, with reasonable enrichment, the LC-MS/MS-based assay 
allowed for the detection of cTnI (1-10 ng/mL) from ≈ 1 mL of plasma from a patient 
who experienced myocardial infarction. However, the current sensitivity of the LC-
MS/MS would not be able to detect cTnI levels in healthy individuals (≈ 1-10 pg/mL) 
Figure 4.5 Representative MRM chromatograms of cTnI (from SRM 2921 digest), monitoring two 
transitions of the unlabeled cTnI peptides (NITEIADLTQK and TLLLQIAK) at the (a) absolute limits 





even if full recovery (100%) of cTnI from plasma was achieved during magnetic 
particle-based immunoaffinity enrichment. 
4.3.2. Recovery efficiency of the magnetic particle-based protein 
immunoaffinity enrichment 
Sensitivity of the LC-MS/MS-based assay is also dependent on the enrichment 
step; therefore, recovery of cTnI was optimized. An increasing amount of antibody-
nanoparticle conjugates (20 µL, 30 µL, 40 µL, 50 µL) were incubated in buffer (0.2 
% BSA in PBS, 1.8 mL) with a fixed amount of cTnI (SRM 2921, 35 ng) for 8 hours. 
Percent recovery of cTnI was determined by LC-MS/MS analysis using external 
calibration curves with SRM 2921 as the calibrant and isotopically labeled peptide 
internal standards (NITEIADL*TQK and TLLLIQA*K).  As depicted in Figure 4.6, 
cTnI recovery saturated at 92.5 % with the addition of 30 µL of antibody-nanoparticle 
Figure 4.6 Percent recovery of cTnI was tested using different volumes of antibody-
nanoparticle conjugates during immunoaffinity enrichment. Quantification was determined 
by analyzing two transitions for two cTnI peptides. The standard deviation error bars 




conjugates (≈ 4.5 µg antibody). Protein low-retention microtubes were used for all 
cTnI studies; however, losses due to protein/peptide adsorption to the microtubes or 
during trypsin digestion may account for the unrecovered cTnI. 
Recovery of cTnI was also evaluated by varying the incubation time of the 
immunoaffinity enrichment process utilizing goat serum as a proof-of-concept 
medium. Goat serum acted as a cTnI-negative control matrix for initial method 
optimization studies because the reagent was cheap and easily accessible. cTnI was 
not expected to be present in the goat serum, however any trace of native cTnI would 
be distinguishable from the spiked cTnI from SRM 2921 due to the variation in amino 
acid sequence. Each targeted human cTnI peptide (TLLLQIAK and NITEIADLTQK) 
varied from the goat cTnI peptides (TLMLQIAK and NITEIADLNQK) by one 
amino acid, which would change the overall mass of the goat cTnI peptides, allowing 
the peptides to pass through MRM analysis undetected.  
Constant amounts of cTnI (35 ng) and anti-cTnI antibody-nanoparticle 
conjugates were spiked into goat serum (0.9 mL; followed by 2x dilution, final 1.8 
mL). The samples were incubated for 1, 2, 4, 8, 12, 16, 20, and 24 hours at room 
temperature with rotary mixing. The samples were then washed using a magnetic 
separator, digested, and reconstituted with isotopically labeled peptide internal 
standards prior to LC-MS/MS analysis. In addition, a negative control sample set was 
tested, which involved adding nanoparticles immobilized with antibody not specific 




The highest percent recovery (68 %) of cTnI was achieved after a 20-hour 
incubation period as shown in Figure 4.7. Percent recovery of cTnI was determined 
by averaging the recoveries of each individual peptide using different transitions, 
which correlated to the overall percent recovery of cTnI. Large standard deviations 
were observed at the 12, 16, 20, and 24-hour incubation time points, which were due 
to the high variability between peptide measurements associated with stability and 
digestion differences. cTnI recovery can also be depicted for each individual peptide, 
as shown in Figure 4.8. Deviations of percent recovery between the NITEIADLTQK 
Figure 4.7 Percent recovery of cTnI (at the protein level) from diluted goat serum following a range of 
incubation time periods. Quantification was determined by analyzing two transitions for each cTnI 
peptides; followed by averaging the four transitions (total) for overall cTnI recovery. For the positive 
control samples, the standard deviation error bars represent all of the monitored transitions from 
triplicate sample preparations. For the negative control samples, the standard deviation error bars 




and TLLLQIAK peptides occurred after the 8-hour incubation time point. Unlike 
TLLLQIAK, NITEIADLTQK is located outside of the stable region (30-110 amino 
acid range) of cTnI and therefore may be degraded or modified in serum after 8 
hours. Lower recovery of NITEIADLTQK, which contains an N-linked glycosylation 
motif, may also result from glycosylation modification; however, no reference to 
glycosylation of this peptide has been documented in the literature.140 Ideally, 
recoveries from the two peptides should agree for accurate and precise quantification 
results. In order to achieve the highest recovery while maintaining comparable results 
among the peptides, an 8-hour incubation period was used for future cTnI enrichment 
studies. As a result, a 50 % recovery of cTnI was expected from serum samples. 
Recovery and repeatability of the assay were evaluated by analyzing three 
replicates of cTnI (from SRM 2921) spiked at three levels (5, 10, 15 ng) in goat 
Figure 4.8 Percent recovery of cTnI (at the peptide level) from diluted goat serum following a range 
of incubation time periods. Quantification was determined by analyzing two transitions for each cTnI 
peptide. The standard deviation error bars represent the monitored transitions per peptide from 




serum on three different days. These levels represent the medium to high range of 
cTnI levels in ≈ 1 mL from plasma or serum of patients who have experienced 
myocardial infarction.23,141 Calibration curves were obtained by plotting the peak area 
ratios of cTnI peptide (from SRM 2921) to peptide internal standard versus known 
concentration ratios of SRM 2921 to each peptide internal standard. The calculated 
intra- and inter-day percent recovery and precision (percent coefficient of variation, 
% CV) of the assay are shown in Table 4.2.  
After demonstrating the repeatability of the method, recovery of spiked 
samples of cTnI near pathological levels from human donor plasma was evaluated for 
proof-of-principle. SRM 2921 (5, 10, and 15 ng) was spiked into normal human 
plasma (≈ 0.9 mL) and diluted 2-fold with PBS. cTnI was then quantified by 
immunoaffinity capture and ID-LC-MS/MS analysis. As shown in Figure 4.9, 
approximately 28 % of cTnI was recovered from plasma after an 8-hour incubation 




period. The lower recovery in human matrix when compared to the goat serum matrix 
was attributed to the increased sample complexity.  The goat serum was sterile-
filtered by the vendor, which reduced the complexity of the matrix and allowed for 
improved recovery efficiency. Moreover, previous studies published in the literature 
show that significant protein losses can occur during sample preparation, especially 
when trying to enrich low abundant proteins from highly complex matrices like 
human plasma.81,142Although a relatively low percent recovery of SRM 2921 from 
normal human plasma was achieved, this workflow provided enough enrichment to 
analyze cTnI at pathological levels.   
During the recovery studies, the isotopically labeled cTnI peptide internal 
standard was added in the final step of the sample preparation workflow (i.e. after 
immunocapture and digestion) prior to LC-MS/MS analysis. For the internal standard 
to be most effective, it should be present during all stages of the sample preparation, 
Figure 4.9 Percent recovery of cTnI (at the protein level) from normal plasma at three different 
amounts. Quantification was determined by analyzing two transitions of two cTnI peptides. The 





especially since it was clear from the recovery studies that large protein losses 
occurred throughout the workflow.70 Therefore, a full-length isotopically labeled 
protein internal standard, instead of a labeled peptide internal standard, was utilized in 
the ID-LC-MS/MS-based assay to improve cTnI measurement quality. Provided that 
the isotopically labeled protein behaves exactly like cTnI, the internal standard can 
correct for protein losses during sample enrichment and compensate for variable 
digestion yields.84,143  
The commercial isotopically labeled cTnI protein was first digested and 
analyzed by LC-MS/MS (ion trap) to verify that lysine (K-13C6, 
15N2) and arginine 
(R-13C6, 
15N4) residues were labeled and that the peptide sequence matched to human 
cTnI. Figure 4.10 shows the extracted ion chromatograms of labeled TLLLQIAK* 
Figure 4.10 Extracted ion chromatograms of TLLLQIAK* and NITEIADLTQK* from a digest of 
isotopically labeled cTnI protein internal standard. Asterisk indicates the isotopically labeled amino 




and NITEIADLTQK*. Compared to the synthetic isotopically labeled cTnI peptides 
(NITEIADL*TQK where L* represents L-13C6 and TLLLQIA*K where A* 
represents A-13C3, 
15N) that were used as the internal standard for recovery studies, 
the isotopically labeled cTnI was labeled at lysine or arginine amino acids, which 
changed the mass of the labeled peptides used for quantification. Therefore, MRM 
transitions were adjusted to monitor tryptic peptides derived from the isotopically 
labeled cTnI protein, as shown in Table 4.3. Similarly, the digested cTnI protein  
internal standard was analyzed via MRM analysis using the LC-MS/MS (triple 
quadrupole) to check isotope incorporation level on the labeled amino acid residues. 
Labeled and unlabeled cTnI peptides with their specific MRM transition were  
targeted during LC-MS/MS analysis, and peak areas from the unlabeled peptides  
 
were compared to the labeled peptides.  Figure 4.11 shows a representative 
chromatogram of cTnI tryptic peptides from the digested isotopically labeled cTnI 
protein sample. The protein standard was 99.7 % isotopically labeled, and no 
correction was applied during data analysis to account for the negligible 0.3 % 
unlabeled form. This data was in agreement with data provided from the vendor.  
Table 4.3 MRM transitions of NITEIADLTQK* and TLLLQIAK* from the isotopically 




For proof-of-concept, five replicates of SRM 2921 and isotopically labeled 
cTnI were spiked into normal human plasma, enriched and digested for LC-MS/MS 
measurement. Matrix-matched calibrants were also prepared by spiking normal 
plasma with a range of concentrations of SRM 2921 and a defined concentration of 
isotopically labeled cTnI. ID-LC-MS/MS analysis revealed that > 90 % (CV = 5.0 %) 
of cTnI had been recovered throughout all of the sample processing steps, indicating 
the isotopically labeled cTnI internal standard acted similarly to SRM 2921 
throughout the analytical workflow and corrected for most biases linked to protein 
losses during enrichment and digestion. Therefore, the isotopically labeled protein 
was selected as an internal standard for quantification of endogenous cTnI in patient 
plasma samples. 
Figure 4.11 Representative MRM chromatograms of digested isotopically labeled cTnI protein 
internal standard to determine isotope incorporation level. Unlabeled and labeled MRM transitions for 





4.3.3. cTnI quantification in patient plasma samples 
The developed method was applied to the analysis of cTnI in (de-identified) 
myocardial patient plasma samples obtained from the University of Washington. 
Human subjects research determination forms can be found in Appendix A. cTnI-
positive patient samples needed to be obtained from a clinical medicine laboratory 
since elevated concentrations of cTnI are highest approximately 18 ± 24 hours after 
the onset of a myocardial infarction. Additionally, only 0.5 mL to 2 mL of leftover 
plasma from each consented patient was provided; therefore, individual patient 
samples had to be pooled for replicate sample preparations.  
To determine repeatability of the assay, five replicates were prepared from a 
pooled myocardial infarction patient plasma sample lot. Isotopically labeled cTnI 
internal standard (≈ 6.66 ng) was spiked into the cTnI-positive pooled patient sample 
prior to sample processing. For cTnI quantification, an external calibration was 
employed by spiking SRM 2921 (≈ 1.22, 2.42, 5.96, 11.9, 18.2 ng) and the 
isotopically labeled cTnI internal standard (≈ 6.66 ng) into negative-cTnI patient 
plasma samples (≈ 0.9 mL) to generate five matrix-matched calibrants. Figure 4.12 
shows a representative MRM chromatogram of cTnI peptides derived from a pooled 
patient plasma sample. The linearity of the external calibration curves for all of the 




The average concentration of endogenous cTnI in plasma was determined to 
be 2.65 ng/mL and the CV was 25.0 % (n = 5), as shown in Table 4.4. Despite 
comparability in the measurement of cTnI by transitions of the same peptide, there 
was considerable discrepancy between the peptides, which increased measurement 
variability and impeded the overall quantification of cTnI in plasma. The acceptable 
range of intra-assay CV is typically below < 20% for quantification of low abundant 
proteins in plasma.43,144  
As speculated in Section 4.3.2, the lower measurement values for 
NITEIADLTQK were likely due to enhanced degradation of the calibrant compared 
to the endogenous form since this peptide is located outside the stable region of cTnI. 
Overall, high variability between peptide measurements could compromise the  
Figure 4.12 MRM chromatogram of cTnI enriched from a pooled cTnI-positive 




applicability of the ID-LC-MS/MS-based assay for robust and accurate measurements 
of a new secondary (matrixed-matched) reference material. To improve the precision 
and accuracy of the quantification results, additional cTnI peptides from different 
regions of the protein were added to the LC-MS/MS method.  
The measurement of a higher number of tryptic peptides has the potential to 
increase the precision and provide higher confidence in the accuracy of cTnI 
quantification. Revisiting Figure 4.3, NIDALSGMEGR and AYATEPHAK peptides 
also produced relatively high MRM signals compared to other cTnI tryptic peptides  
screened by MRM analysis. The tryptic peptide ISADAMMQALLGAR was avoided, 
mainly due to the presence of the serine residue, which has been known to undergo 
phosphorylation.84,145   
In comparison to isotopically labeled peptides, one benefit of using a full-
length isotopically labeled protein as the internal standard is the flexibility to add or 
change the surrogate peptides used to quantify cTnI during LC-MS/MS analysis.142 
The analysis of additional tryptic peptides can also provide information on the  
Figure 4.13 Calibration curves are provided for monitored cTnI peptide transitions as a plot of 
unlabeled : labeled integrated peak area ratios versus unlabeled : labeled measured mass ratios. A 
regression equation of the best-fit line is provided for each plot along with a R2 estimate of the 




stability or heterogeneity of cTnI.136 To this end, the LC-MS/MS method was 
expanded to monitor NIDALSGMEGR and AYATEPHAK as additional surrogate 
cTnI peptides in order to increase the precision of the measurement. The labeled 
versions of these two peptides for each MRM transition were also added for ID-LC-
MS/MS analysis and were determined using the MRM prediction tool, Skyline.55 On 
another note, the AYATEPHAK peptide had a wider MRM peak width and a slightly 
less stable retention time compared to other cTnI peptides; therefore, the dynamic 
MRM window for that particular peptide was extended to ± 3 minutes, and 
AYATEPHAK did not co-elute or interfere with other monitored peptides. Dynamic 
MRM monitors individual peptides at specific retention times only; therefore, if the 
MRM window is too narrow, the AYATEPHAK may not be completely detected 
during elution, which would negatively affect quantification. 
A proof-of-principle experiment was performed to determine the effect of two 
additional tryptic peptides on the average cTnI measurement. To assess recovery of 
Table 4.4 cTnI levels in five replicate sample preparations from a pooled myocardial infarction patient 




the additional peptides, known constant amounts (12.5 ng) of SRM 2921 and 
isotopically labeled cTnI internal standard were spiked into normal human plasma (n 
= 5). A matrixed-matched calibration was also generated by spiking SRM 2921 (≈ 
1.34, 2.61, 12.5, 25.6, 37.8 ng) and isotopically labeled protein internal standard (≈ 
12.5 ng) into normal human plasma (≈ 0.9 mL). Samples and calibrants were then 
enriched using magnetic particle-based immunoaffinity enrichment, digested with 
trypsin and prepared for LC-MS/MS analysis. Figure 4.14 shows a representative 
MRM chromatogram from one of the five replicates.  
It is important to note that neither the unlabeled nor labeled NIDALSGMEGR 
peptide was detected in any of the samples, which supports the hypothesis that SRM 
2921 in plasma matrix is degrading or modifying near the C-terminus of the cTnI 
protein. Conversely, AYATEPHAK, which is located near and within the stable 
Figure 4.14 MRM chromatogram of cTnI recovered from normal plasma samples (spiked with SRM 
2921). Two transitions from each (unlabeled and labeled) cTnI peptide, AYATEPHAK, 
NIDALSGMEGR, NITEIADLTQK and TLLLQIAK were monitored. Two transitions for (unlabeled 




region of cTnI, was reproducibly detected in the digested samples, enabling it to be 
used for cTnI quantification. Overall recovery of cTnI was > 90% with CV ≤ 6.31 % 
for the five replicate samples. To this end, Table 4.5 shows the updated MRM 
transition list for the three cTnI tryptic peptides used for quantification and one 
antibody tryptic peptide used as a qualitative control to assess the antibody-magnetic 
particle enrichment. 
After confirming sufficient peptide recovery and measurement precision, the 
magnetic nanoparticle-based immunoaffinity approach coupled with targeted LC- 
MS/MS was applied to quantify cTnI concentrations in five individual cTnI-positive 
patient plasma samples. Calibration curves were generated by spiking known  
Table 4.5 Updated MRM transitions of cTnI surrogate peptides used for quantification, 





amounts of SRM 2921 (≈ 1.78, 2.48, 6.04, 12.1, 18.4, 24.5 ng) and isotopically 
labeled protein internal standard (≈ 12.1 ng) into cTnI-negative patient plasma (≈ 0.9 
mL). Individual myocardial infarction patient plasma samples (≈ 0.9 mL) were spiked 
with defined amounts (≈ 12.1 ng) of isotopically labeled protein internal standard. 
cTnI was captured from the samples and calibrants by magnetic nanoparticle-based 
immunoaffinity enrichment, washed, and digested with trypsin. Isotopically labeled  
DLPSPIE*R, a surrogate peptide from the constant region of the anti-cTnI antibody, 
was prepared at 0.0466 ng/µL and used to reconstitute the digests (10 µL final 
volume) prior to LC-MS/MS analysis. 
Figure 4.15 shows a representative MRM chromatogram of the tryptic 
peptides used to quantify cTnI concentration in an individual myocardial infarction 
Figure 4.15 Representative MRM chromatogram of cTnI enriched from an individual cTnI-positive 




patient plasma sample. As shown in Figure 4.16, the method was linear between 1.98 
ng/mL and 27.2 ng/mL with R2 ≥ 0.994 for all monitored transitions. Using a matrix-
matched calibration, peptide concentrations from a total of six transitions were 
calculated and averaged to determine the overall cTnI concentration for each 
individual patient plasma sample. Overall cTnI concentrations ranged between 4.83 
ng/mL and 11.3 ng/mL with CV’s ≤ 14.3 % for the five patient samples, as 
demonstrated in Table 4.6.   
Quantifying three cTnI tryptic peptides simultaneously and independently 
provided confidence in the accuracy of the ID-LC-MS/MS measurement results.138 
Based on the data, it was important to choose surrogate peptides within or near the 
stable region of cTnI for bottom-up ID-LC-MS/MS analysis. Results indicated that 
Figure 4.16 Calibration curves are provided for monitored cTnI peptide transitions as a plot of 
unlabeled : labeled integrated peak area ratios versus unlabeled : labeled measured mass ratios. A 
regression equation of the best-fit line is provided for each plot along with a R2 estimate of the 




cTnI in both SRM 2921 and recombinant isotopically labeled protein degrades near 
the C-terminus of cTnI once spiked into plasma. Therefore, surrogate peptides should 
be avoided near this region.  
4.4. Conclusion 
An immunoaffinity enrichment strategy based on magnetic particle-based 
separation was utilized to selectively isolate cTnI from clinical patient samples, such 
as plasma. Following immunocapture, cTnI was digested with trypsin to release 
surrogate tryptic peptides for LC-MS/MS analysis. The success of the enrichment 
approach was measured by experimentally determining percent recovery of cTnI (SRM 
2921) from different matrices using ID-LC-MS/MS analysis with isotopically labeled 
peptide internal standards. Significant protein losses were expected during enrichment 
because cTnI is in low abundance, even in plasma samples from myocardial infarction 
patients. Following method development, an isotopically labeled protein internal standard 




was utilized to account for protein losses and digestion variability, and enabled accurate 
protein quantification.  
Overall, the ID-LC-MS/MS assay coupled with immunoaffinity enrichment 
was able to quantify low abundant cTnI in human plasma in the low ng/mL range 
with excellent CV’s using three surrogate cTnI peptides. This work demonstrates 
significant improvements in magnetic particle-based immunoaffinity enrichment 
techniques and LC-MS/MS detection limits for the analysis of cTnI in patient 
samples. Furthermore, this method has the potential to act as a candidate reference 
measurement procedure for value assignment of cTnI in serum-based reference 





Chapter 5: cTnI analysis by peptide immunoaffinity enrichment 
and LC-MS/MS analysis 
5.1. Introduction 
As an alternative to protein immunoaffinity enrichment as described in 
Chapter 4, another enrichment strategy for cTnI involves using anti-peptide 
antibodies coupled to magnetic particles to capture and isolate cTnI at the peptide 
level rather than at the protein level by first performing a proteolytic digestion on the 
sample. Peptide enrichment by anti-peptide antibodies (also termed SISCAPA) 
coupled with MRM analysis has been reported to achieve limits of detection of ≈ 1 
ng/mL for proteins using as little as 10 µL of plasma.67,96,140,146 Anti-peptide 
antibodies can be generated against specific peptides from the target protein.52,92 The 
drawback is that a unique antibody has to be generated for each peptide of interest, 
which is relatively expensive (ranging upwards of $2000 per anti-peptide antibody) 
and requires a long lead time (3-4 months).86,147 Although the production of anti-
peptide antibodies is a lengthy and expensive process, the combination of peptide 
immunoaffinity enrichment with LC-MS/MS analysis is advantageous for cTnI 
quantification for two reasons. First, interferences caused by autoantibodies or 
antireagent antibodies are avoided because these proteins are enzymatically digested 
early in the sample preparation workflow. Second, the assay has the ability to readily 
multiplex with other targets, such as peptides derived from cTnT and cTnC, which 
would allow quantification of the entire cardiac troponin complex in a single 
reference measurement procedure.28,89 Using this approach, anti-peptide antibodies 




digested plasma and serum samples.76,86,148 The captured cTnI peptides can be then 
released from the antibody-magnetic particles and analyzed via LC-MS/MS. 
This work aims to improve upon previously published SISCAPA-LC-MS/MS 
work by capturing two surrogate peptides from cTnI in plasma. In 2009, Kuhn et 
al.140 reported a LC-MS/MS-based method coupled with peptide immunoaffinity 
enrichment to quantify cTnI in plasma using a single peptide (NITEIADLTQK).  In 
this chapter, anti-peptide antibodies were raised against NITEIADLTQK and 
TLLLQIAK for cTnI peptide capture studies. In general, developing a peptide and 
protein immunoaffinity enrichment method coupled with LC-MS/MS analysis can 
ultimately be used to postulate the true values of cTnI in plasma and serum. A higher 
confidence in the certified value of cTnI in a serum-based reference material can be 
achieved if both enrichment methods are used to analyze identical clinical samples 
and a small % CV is calculated between the two methods.  
In this chapter, preliminary cTnI peptide recovery studies demonstrating 
proof-of-principle are presented. Additionally, some existing and foreseen challenges 
are discussed regarding the development of a peptide immunoaffinity enrichment 
method for cTnI. Key steps in the workflow include target peptide selection, anti-
peptide antibody reagent production, and optimization of the digestion, peptide 




5.2. Experimental design 
5.2.1. Materials  
Rabbit anti-peptide polyclonal antibodies specific for cTnI surrogate peptides 
NITEIADLTQK and TLLLQIAK were produced by Pacific Immunology (California, 
USA).  Briefly, the selected peptides were synthesized with an N-terminal cysteine, 
conjugated to KLH, and the KLH/adjuvant formulations were then injected into two 
rabbits (per peptide) following a 13-week antibody production protocol. Antisera 
were tested by ELISA and reactive bleeds (against the two peptides) were selected for 
purification via affinity chromatography. Purified polyclonal antibodies were stored 
at -20 °C in PBS, pH 7.4 containing 0.02 % (w/v) sodium azide. 
SRM 2921 – Human cardiac troponin complex was obtained from NIST. The 
synthetic isotopically labeled peptides, NITEIADL*TQK and TLLLQIA*K were 
purchased from AnaSpec, Inc. (California, USA). A donor plasma pool, collected 
from 50 apparent healthy individuals, was obtained through Golden West Biologicals, 
Inc. (California, USA). Rapigest™ SF was purchased from Waters Corporation 
(Massachusetts, USA) and trypsin gold, MS grade, was purchased from Promega 
Corporation (Wisconsin, USA). High purity LC-MS grade water (H2O)/formic acid 
and acetonitrile (ACN) /formic acid were purchased from Honeywell-Burdick and 
Jackson (Michigan, USA). Protein LoBind centrifuge tubes were purchased from 
Eppendorf (New York, USA). All other chemicals were purchased from Sigma-




5.2.2. Immobilization of anti-peptide polyclonal antibodies onto 
magnetic nanoparticles 
Polyclonal anti-NITEIADLTQK and anti-TLLLQIAK antibodies were 
immobilized on the magnetic nanoparticles using the glutaraldehyde method, as 
described in Section 4.2.2. After conjugation, blocking, and wash steps, the antibody-
nanoparticle conjugates were reconstituted in ammonium bicarbonate (0.25 mL). The 
resultant nanoparticle sample contained 4 mg/mL nanoparticles. A single batch of 
antibody-magnetic nanoparticle conjugates were prepared for each peptide, and then 
combined to form one lot of antibody-nanoparticle conjugates for use in cTnI peptide 
capture studies. 
5.2.3. Calibrant and sample preparation for recovery studies 
Human cardiac troponin complex (cTnI, cTnT, cTnC) from NIST SRM 2921 
stock was thawed to room temperature and prepared gravimetrically by diluting SRM 
2921 in 0.1 % BSA solution in ammonium bicarbonate. SRM 2921 solution was 
added at discrete amounts (e.g., ≈ 1.3, 2.5, 5.0, 10, 20 ng) and diluted up to 40 µL 
with 0.1 % (w/v) BSA in ammonium bicarbonate (pH 7.8) solution. Known amounts 
of SRM 2921 (5, 10, 15 ng) were added to centrifuge tubes and diluted up to 40 µL 
with 0.1 % (w/v) BSA in ammonium bicarbonate solution. All samples were prepared 
in duplicate. 
The samples and calibrants were denatured in 0.2 % (v/v) Rapigest™ SF in 50 
mmol/L ammonium bicarbonate (40 µL) and boiled for 2 minutes. The proteins were 
reduced with a final concentration of 10 mmol/L DTT at 60 °C with shaking for 45 




minutes. Trypsin was added to the samples (1:2.5 w/w trypsin-to-protein ratio) and all 
samples were incubated for 16 hours at 37 °C. The digests were acidified with a final 
concentration of 5 % (v/v) formic acid for 45 minutes at 37 °C and centrifuged at 4 
°C to remove the Rapigest™ SF. The digests were transferred to fresh centrifuge 
tubes and then dried using a vacuum centrifuge. Calibrants were reconstituted with 30 
µL antibody-magnetic nanoparticles and diluted up to 40 µL with ammonium 
bicarbonate. To ensure complete recovery, the calibrants did not undergo the 
following enrichment or wash steps.  
To capture NITEIADLTQK and TLLLQIAK peptides, samples were 
reconstituted in 0.9 mL PBS, pH 7.4, and then 30 µL of antibody-magnetic 
nanoparticle conjugates were added. Samples were incubated at room temperature 
with gentle rotary mixing for 8 hours. Following incubation, non-specific peptides 
were removed from the samples by washing the nanoparticles two times with tris 
buffer (20 mmol/L tris, 150 mmol/L sodium chloride) containing 0.05 % (v/v) Tween 
20 (0.9 mL) and once with ammonium bicarbonate (0.9 mL). The samples were 
resuspended in ammonium bicarbonate (40 µL) for a second digestion. 
Captured peptides and anti-peptide antibodies were released from the 
magnetic nanoparticles by denaturation. The samples and calibrants were denatured 
in 0.2 % (v/v) Rapigest™ SF in 50 mmol/L ammonium bicarbonate (40 µL) and 
boiled for 2 minutes. Trypsin was added to the samples (1:10 w/w trypsin-to-protein 
ratio) and all samples were incubated for 2 hours at 37 °C. The digests were acidified 
with a final concentration of 5 % (v/v) formic acid for 45 minutes at 37 °C and 




digests were transferred to fresh autosampler vials and then dried using a vacuum 
centrifuge.  
Isotopically labeled peptides (TLLLQIA[13C3,
15N]K and 
NITEIADL[13C6]TQK, were prepared at constant concentrations for use as internal 
standards. Calibrants and samples were reconstituted with the isotopically labeled 
peptide internal standard solution (10 µL) prior to LC-MS/MS analysis. 
5.2.4. LC-MS/MS analysis 
LC-MS/MS (dynamic MRM) analysis was performed on an Agilent 1200 LC 
system coupled in-line with an Agilent 6490 triple quadrupole MS as described in 
Section 4.2.6. Two fragmentation transitions were monitored by dynamic MRM for 
two cTnI peptides (NITEIADLTQK and TLLLQIAK) for both the isotopically 
labeled and unlabeled peptides, as shown in Table 5.1.  Delta retention time windows 
were set to 1 minute for each MRM transition. Data analysis was performed as 
described in Section 4.2.6. 
Table 5.1 Optimized MS parameters and monitored transitions for cTnI identification and 




5.3. Results and discussion 
5.3.1. Polyclonal anti-peptide antibodies 
NITEIADLTQK and TLLLQIAK peptide sequences were used to generate 
anti-peptides antibodies for cTnI peptide immunoaffinity enrichment. These peptides 
were selected based on their detectability and high LC-MS/MS signal responses after 
trypsin digestion of cTnI (from SRM 2921), as described in Section 4.3.1.  
Polyclonal antibody production yields (provided from the vendor) were highly 
variable. The anti-TLLLQIAK antibody only yielded ≈ 1 mg after immunization and 
purification using two rabbits, whereas the anti-NITEIADLTQK antibody yields were 
≈ 24 mg. TLLLQIAK was predicted to be less immunogenic than NITEIADLTQK 
due to its hydrophobic nature and short peptide length. Therefore, an additional four 
rabbits were immunized by the vendor to generate higher anti-TLLLQIAK antibody 
yields. Antisera was titrated and measured by ELISA in all four rabbits, and the two 
rabbits producing the highest titers proceeded with the 13-week protocol. The second 
immunization project produced ≈ 1.75 mg of anti-TLLLQIAK antibody.  Because the 
anti-TLLLQIAK antibody was limited in supply, few preliminary studies could be 
performed.  
5.3.2. Magnetic particle-based peptide immunoaffinity recovery 
Percent recovery studies were performed to initially evaluate the peptide 
immunoaffinity enrichment workflow and demonstrate proof-of-principle. cTnI (from 
SRM 2921) was spiked at three different levels (5, 10, 15 ng) into an ammonium 
bicarbonate solution containing 0.1 % BSA.  Samples were digested with trypsin, and 




to magnetic nanoparticles; followed by a second digestion to release the peptides and 
antibodies from the magnetic nanoparticles. Isotopically labeled peptide internal 
standards were spiked into the samples prior to LC-MS/MS analysis. Figure 5.1 
shows a representative MRM chromatogram of cTnI peptides simultaneously 
captured from a buffered solution using peptide immunoaffinity enrichment.  
Percent recovery of cTnI was determined by LC-MS/MS analysis using 
external calibration curves with SRM 2921 as the calibrant and isotopically labeled 
peptide internal standards (NITEIADL*TQK and TLLLQIA*K). The linearity of the 
external calibration curves for all of the monitored transitions was demonstrated to be 
≥ 0.994, as shown in Figure 5.2.  
 
 
Figure 5.1 MRM chromatogram of cTnI enriched from buffer using magnetic nanoparticle-based 




As shown in Figure 5.3, percent recoveries of NITEIADLTQK from buffer 
ranged from 27 % to 38 % with CV’s ≤ 7.0 %, indicating that the assay needed to be 
further optimized to improve antibody capture and digestion efficiency. Furthermore, 
recoveries for TLLLQIAK were lower and only ranged between 6.1 % and 17 % with 
CV’s ≤ 7.6 %.  It appeared that TLLLQIAK elicited a weaker antibody response than 
the NITEIADLTQK peptide, as evidenced by the lower recoveries.  
Peptide recoveries were also examined by spiking constant amounts of SRM 
2921 (35 ng) into buffer (0.1 % BSA in ammonium bicarbonate, 30 µL) and normal 
human plasma (30 µL). An isotopically labeled peptide internal standard was added 
after sample processing and used to estimate percent recoveries for each peptide via a 
one-point calibration curve. Figure 5.4 shows MRM chromatograms of cTnI peptides 
captured from buffer and plasma. As predicted, a higher relative percent recovery of 
each cTnI peptide was achieved when peptide immunoaffinity enrichment was 
performed in buffer rather than plasma. For example, approximately 15 % of 
Figure 5.2 Calibration curves are provided for monitored cTnI peptide transitions as a plot of 
unlabeled : labeled integrated peak area ratios versus unlabeled : labeled measured mass ratios. A 
regression equation of the best-fit line is provided for each plot along with a R2 estimate of the 




NITEIADLTQK was recovered from the buffer matrix compared to the ≈ 5 % 
recovery from plasma. Relative percent recoveries of TLLLQIAK were estimated to 
be < 1 % in both matrices, suggesting that the peptide has poor antigenicity to the 
polyclonal anti-TLLLQIAK antibody and that the workflow needed further 
optimization.   
Overall percent recoveries varied between NITEIADLTQK and TLLLQIAK 
during the preliminary studies, which was determined by adding an isotopically 
labeled peptide internal standard in the final step of the sample preparation (i.e. after 
digestion, immunocapture and peptide release) prior to LC-MS/MS analysis. Ideally, 
the isotopically labeled peptide internal standard can be added as early as the 
immunoaffinity capture step. By spiking the isotopically labeled peptide internal 
standard at different steps in the workflow following digestion (i.e. immunoaffinity 
Figure 5.3 Percent recovery of cTnI (at the peptide level) spiked into buffer at three different 
amounts. Quantification was determined by analyzing two transitions for two cTnI peptides. The 





capture and peptide release steps), peptide recoveries can be evaluated to provide 
insight into which steps need additional optimization. An example of this is shown in 
Appendix B. After method development, an isotopically labeled protein internal 
standard can be incorporated into the workflow to account for the digestion step, a 
well-known source of variability.  The protein internal standard can correct for most 
biases linked to peptide losses during digestion, enrichment, and release, as 
demonstrated in sections 4.3.2 and 4.3.3. 
5.3.3. Potential considerations for improvement of cTnI recovery via 
peptide immunoaffinity enrichment in further studies 
In order to quantify cTnI at the low or sub ng/mL range using peptide 
immunoaffinity enrichment, large volumes of human plasma (i.e. ≈ 1 mL) may need 
Figure 5.4 Representative MRM chromatograms of spiked cTnI enriched from (a) buffer and (b) 





to be digested. During preliminary studies, reduction (with DTT) and alkylation (with 
IAM) of 30 µL plasma made the sample cloudy, suggesting that some of the 
denatured proteins formed aggregates. Overnight digestion with trypsin, however, 
made the solution less opaque.149 Insolubility of protein aggregates can hinder trypsin 
digestion and cause protein/peptide losses.150 Therefore, the current trypsin digestion 
protocol needs to be optimized and scalable to 1 mL of plasma. Razavi et al.151 have 
reported an “addition only” method to efficiently and reproducibly digest 1 mL of 
plasma using urea as the denaturant and tris-(2-carboxeythl)phosphine (TCEP) as the 
reducing agent prior to peptide immunoaffinity enrichment. This protocol may be a 
better approach to digest large volumes of plasma for cTnI peptide immunoaffinity 
studies.  
A second digestion step was performed to release cTnI peptides from the 
antibody-magnetic nanoparticle conjugates. During preliminary studies, bound 
peptides were initially released from the antibody via elution using 5 % acetic acid. 
However, acid elution demonstrated inconsistent removal of peptides between 
replicate samples. Therefore, a quick on-particle digestion was performed to release 
the cTnI peptides and antibodies from the magnetic nanoparticles. However, the 
antibodies cannot be reused if the sample is digested to release the captured peptides. 
Zhao et al.152 demonstrated that polyclonal antibodies (conjugated to magnetic beads) 
can be recycled after stripping off bound peptide analytes via acid washing using 5 % 
acetic acid with 3% acetonitrile in water. In the multiplexed assay tested by Zhao et 
al., antibodies were regenerated after each acid wash and reused for least 10 peptide 




polyclonal antibodies via acid washing would enable more studies for assay 
development and application, while reducing overall assay cost.94,152 It would also 
extend the productive life of limited resources, such as the anti-TLLLQIAK antibody.  
5.4. Conclusion  
 
Peptide immunoaffinity enrichment coupled with LC-MS/MS analysis has the 
potential for high sensitivity LC-MS/MS analysis and allows for a highly multiplexed 
quantitative assay. Preliminary studies using polyclonal anti-peptide antibodies to 
capture NITEIADLTQK and TLLLQIAK peptides were described for enrichment of 
cTnI. These peptides were selected to be surrogate peptides for cTnI, which would 
allow a comparison between the two enrichment (peptide and protein) methods. 
Evaluation and method development of the peptide immunoaffinity 
enrichment workflow was restricted due to the limited resource of anti-TLLLQIAK 
antibody. Polyclonal antibody production can be highly variable, with the anti-
TLLLQIAK antibody only yielding ≈ 1-2 mg of antibody due to its poor 
immunogenicity.  Other cTnI peptides may prove to be better surrogate peptides for 
cTnI peptide capture.  For instance, AYATEPHAK has a higher predicted 
immunogenicity for polyclonal antibody production, and it possesses high LC-
MS/MS ionization efficiency.  
Furthermore, a trypsin digestion protocol for large plasma/serum volumes also 
needs to be further optimized to improve digestion efficiencies prior to 
immunocapture. Various elution methods should also be evaluated to recover the 




recovery of cTnI. The ideal eluent would be able to retain the polyclonal antibodies 
on the magnetic nanoparticles for regeneration and reuse in additional immunoaffinity 
capture studies. However, this work demonstrates two proof-of-concept studies and 
the potential for peptide immunoaffinity capture as another enrichment strategy for 




Chapter 6: Summary and outlook 
Measurement of cTnI in patient samples by immunoassays is already a useful 
clinical tool for detecting cardiac damage; however, the clinical community also 
recognizes that these immunoassays need improvement with respect to specificity and 
standardization. As such, the ultimate goal of this work was to develop a robust and 
traceable reference measurement procedure to certify concentration values of cTnI in 
a serum-based reference material, which can then be used by different immunoassay 
manufacturers to evaluate and harmonize the performance of their products. ID-LC-
MS/MS is considered the gold standard for protein quantification. However, unlike 
immunoassay, the sensitivity and relatively small dynamic range of LC-MS/MS has 
been insufficient to measure concentrations of cTnI in serum. Therefore, the specific 
aim of this dissertation was to develop novel magnetic particle-based immunoaffinity 
enrichment strategies to isolate and enrich cTnI from serum and plasma for improved 
LC-MS/MS detection. 
6.1. Summary 
In this dissertation, silica coated magnetic nanoparticles with an average size 
of 85 nm were synthesized and used as solid supports for immunoaffinity enrichment. 
The spherical magnetic nanoparticles exhibited good monodispersity, maintained 
high paramagnetic properties and dispersed well in aqueous buffered solution, which 
were important characteristics to be of practical use for immunoaffinity enrichment 
applications. Furthermore, various immobilization strategies were investigated to bind 




onto magnetic particles was a critical step in the enrichment process and directly 
influenced the performance of the targeted separation. As such, an ID-LC-MS/MS 
method was developed to accurately quantify the amount of antibody bound to 
magnetic particles. Using this method, two antibody immobilization strategies 
(glutaraldehyde versus epoxide reaction) and two different magnetic particle sizes 
(synthesized nanoparticles versus commercial microparticles) were evaluated. This 
study demonstrated that nanoparticles more efficiently bound antibody compared to 
microparticles due to the larger surface area-to-mass ratio. Higher antibody loading 
was thought to result in higher protein capture efficiency.  
The optimized antibody-magnetic nanoparticle conjugates were then utilized 
to capture cTnI from various biological matrices and analyzed by ID-LC-MS/MS. 
Comprehensive optimization studies were undertaken to improve the overall recovery 
of cTnI during enrichment and subsequent sample processing. During method 
validation, the LC-MS/MS-based assay coupled with protein immunoaffinity 
enrichment demonstrated the necessary precision, robustness, and sensitivity to 
accurately quantify cTnI in serum or plasma. Furthermore, results demonstrated that 
surrogate peptides should be chosen near the central region (amino acid residues 30-
110) of cTnI, which is more stable and more resistant to proteolysis or post-
translational modification. In the final LC-MS/MS-based assay, the concentration of 
cTnI in plasma was quantified using an external standard curve with SRM 2921 as the 
mass calibrant and an isotopically labeled cTnI internal standard. The internal 
standard was used to account for instrument variations, as well as protein losses and 




Later work involved application of the optimized protein immunoaffinity 
enrichment technique and ID-LC-MS/MS method for absolute quantification of cTnI 
from plasma of myocardial infarction patient samples. The method was capable of 
measuring cTnI from an individual patient plasma samples at a concentration of ≈ 4 
ng/mL with good precision (CV < 15 %). Therefore, it was concluded that this 
method can be used to postulate true clinical concentration values of cTnI in diseased 
serum or plasma, and in the future, may be utilized to quantify cTnI in a serum-based 
reference material.   
Finally, due to the growing application of peptide immunoaffinity enrichment 
for low abundant protein quantification (via LC-MS/MS detection) reported in the 
literature, a study was undertaken to explore the potential of using magnetic 
nanoparticles coupled with anti-peptide antibodies to capture surrogate cTnI peptides, 
rather than the cTnI protein, for improved LC-MS/MS detection. Anti-peptide 
antibodies raised against NITEIADLTQK and TLLLQIAK were used for capture 
studies. However, in all of the studies, extremely low recoveries of TLLLQIAK after 
peptide immunoaffinity enrichment were observed. Therefore, further method 
development is required. To ensure accurate and reliable measurement, more than one 
surrogate peptide for cTnI should be used for quantification. Overall, the data 
revealed several challenges posed by peptide immunoaffinity enrichment with regard 
to peptide affinity and limited resources of antibody reagents.  However, this proof-




6.2. Outlook and future work 
This work demonstrates progress towards the development of a candidate 
reference measurement procedure for cTnI using immunoaffinity enrichment coupled 
with ID-LC-MS/MS analysis. Due to the limited sensitivity of the LC-MS/MS, a 
magnetic nanoparticle-based immunoaffinity enrichment strategy was needed to 
capture and isolate cTnI, while reducing the complexity and dynamic range of the 
sample. Further attempts will be made to improve the sensitivity and sample 
throughput of the reference measurement procedure.  
Ideally, the objective is to reproducibly quantify cTnI levels in myocardial 
infarction patients (1-10 ng/mL) and healthy donors (1-10 pg/mL) by ID-LC-MS/MS. 
Further, an automated workflow would permit higher sample throughput, reduce 
analyst-to-analyst variation, and improve method reproducibility. Future work will 
focus on implementing the magnetic nanoparticle-based immunoaffinity enrichment 
and digestion protocols onto a liquid handling automation platform. A robotic 
platform will be beneficial for meeting testing demands during value assignment of 
cTnI in a secondary reference material. 
 Moreover, data published in the literature and in this dissertation demonstrate 
the potential of using anti-peptide antibodies to capture cTnI peptides for ID-LC-
MS/MS analysis. However, in order to efficiently enrich cTnI at the peptide level, 
additional efforts are needed to improve overall peptide recovery. In this respect, 
various polyclonal anti-peptides antibodies, digestion approaches, and elution 




peptides should be tested to increase the success rate of antibody production, and to 
develop a more specific and robust assay. 
 Overall, this work highlights significant improvements in magnetic particle-
based protein immunoaffinity enrichment techniques and LC-MS/MS detection for 
the analysis of cTnI in clinical patient samples. However, cTnI may be released and 
available in many forms, such as multiple complexes (e.g., cTnI-cTnC, cTnI-cTnC-
cTnT) or in free form. Expanding the LC-MS/MS method to monitor peptides from 
cTnT and cTnC will shed light on which cTnI form is captured using anti-cTnI 
antibody. Further studies will include characterizing the heterogeneity of cTnI 
captured in patient samples using intact protein LC-MS/MS analysis.  
With magnetic-nanoparticle immunoaffinity enrichment playing a significant 
role in the ID-LC-MS/MS analysis of cTnI, the methods described herein offer 
promise for the development of a reference measurement procedure to support the 
implementation of a reference measurement system for cTnI. It is critical that intra- 
and inter-standardization of cTnI quantification is achieved for improved patient 
treatment and management. Lastly, few reference measurement procedures and 
matrix-based reference materials are available for low abundant clinical protein 
biomarkers. The enrichment protocols and LC-MS/MS methods discussed will also 
provide the necessary tools to develop reference measurement procedures for other 
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Appendix B: Estimation of recovery efficiency of peptide 
immunoaffinity enrichment using Protein A/G beads 
 A known amount of SRM 2921 was spiked into buffer (50 mmol/L 
ammonium bicarbonate containing 0.1 % (w/v) BSA) and digested using the protocol 
described in Section 5.2.3 except that trypsin was added at a 1:40 w/w trypsin-to-
protein ratio. After digestion, the sample was dried and a known amount of 
isotopically labeled peptide (NITEIADL*TQK and TLLLQIA*K) internal standard 
was spiked into the sample. The sample was analyzed by LC-MS/MS analysis to 
determine the amount of unlabeled peptide in the sample relative to the spiked 
internal standard.  
 In another sample, a known amount of SRM 2921 was spiked into buffer (50 
mmol/L ammonium bicarbonate containing 0.1% BSA) and digested using a similar 
protocol as described in Section 5.2.3, except that trypsin was added at a 1:40 w/w 
trypsin-to-protein ratio. Equal amounts (≈ 7 µg) of affinity-purified anti-
NITEIADLTQK antibody and anti-TLLLQIAK antibody (Pocono Rabbit Farm & 
Laboratory Inc., Pennsylvania, USA, in PBS containing 0.02 % (w/v) sodium azide 
and 1 % (w/v) BSA), free in solution, were added to the sample digest and diluted up 
to 500 µL with PBS. The sample was incubated for 2 hours, followed by the addition 
of Protein A/G magnetic beads (25 µL, Pierce™, ThermoFisher Scientific, 
Massachusetts, USA, product number 88802, 10 mg/mL reported concentration). The 
sample was incubated for another 2 hours to subsequently capture the antibodies on 
the magnetic beads. Following incubation, non-specific peptides were removed by 




sodium chloride) containing 0.05 % (v/v) Tween 20 (0.5 mL) and once with water 
(0.5 mL). Captured peptides were eluted two times with 30 µL 5 % acetic acid. The 
eluents were transferred to an autosampler tube and dried using a vacuum centrifuge. 
Isotopically labeled peptide (NITEIADL*TQK and TLLLQIA*K) internal standard 
was used to reconstitute the sample prior to LC-MS/MS analysis. LC-MS/MS 
conditions and analysis are described in Section 5.2.4; however basic MRM analysis 
was used instead of dynamic MRM. Dwell time for each transition was set to 100 
milliseconds. Relative ratio of unlabeled to labeled peptide following the enrichment 
process was compared to the unlabeled to labeled peptide ratio after the digestion step 
(via one-point calibration curve). 
  First, relative recovery (average of 2 transitions for each peptide) from the 
digestion step was approximately 50 % and 83 % for NITEIADLTQK and 
TLLLQIAK, respectively. Peptide recovery from the protein digest (without 
enrichment) was below theoretical, indicating that the digestion step could be further 
optimized. Furthermore, recovery from the entire peptide immunoaffinity workflow 
was demonstrated to be much lower. A recovery of 27 % for NITEIADLTQK was 
achieved and less than 1 % was achieved for TLLLQIAK, which deemed the anti-
TLLLQIAK polyclonal antibody to be non-working. Figure B-1 shows the MRM 
chromatograms from both samples. The experiment was able to identify peptide 











Figure B- 1 Representative MRM chromatograms of cTnI after (a) trypsin digestion only and (b) after 
digestion, peptide immunoaffinity enrichment, and peptide elution. Zoomed inset shows unlabeled 
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